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ABBREVIATIONS 
 
AD Alzheimer’s Disease 
AIF Apoptosis Inducing Factor 
ALS Amyotrophic Lateral Sclerosis 
Apaf-1 Apoptotic Protease Activating Factor-1 
APOE Apolipoptrotein E 
APS Ammonium Persulfate 
ATP Adenosine Triphosphate 
BBB Blood Brain Barrier 
Bcl-2 B-Cell Lymphoma 2 
BSA Bovine serum albumin 
CARA Computer Aided Resonance Assignment 
CD  Circular Dichroism  
Cdk1 Cyclin-dependent kinase-1 
CNS  Central Nervous System  
COSY Correlated Spectroscopy 
CsA Ciclosporin A 
CSP Chemical Shift Perturbation 
CTD  C-terminal Domain  
CypA Cyclophilins 
DABCYL 4-(dimethylaminoazo)benzene-4-carboxylic acid 
DIC Diisopropylcarbodiimide 
DIPEA N,N-Diisopropylethylamine 
DMF N,N-Dimethylformamide 
DMSO Dimethyl sulfoxide 
dNTP  Deoxy Nucleotide Tri-Phosphate  
DR Death Receptor 
DTT  Dithiothreitol  
Endo G Endonuclease G 
ESI  Electron Spray Ionization Source  
ETC Electrons Transport Chain 
FAD Flavin Adenine Dinucleotide 
FasR Fas Receptor 
FPLC  Fast Protein Liquid Chromatography  
FRET Fluorescence resonance energy transfer 
GSH Reduced Glutathione 
GST  Glutathione S-Transferase  
HATU 
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate 
HI Hypoxia/Ischemia 
HOBt 1-hydroxybenzotriazole 
HPLC  High Performance Liquid Chromatography  
Hq Harlequin 
HSP70 Heat Shock Protein 70  
HSQC  Heteronuclear Single Quantum Coherence  
HTS High throughput screening 
Kd  Dissociation Constant  
KDa KiloDalton 
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HCV Hepatitis C Virus 
HIV Human Immunodeficiency Virus 
IAPs Inhibitor of Apoptosis Proteins 
IC50 Concentration Inhibition  
IMM Inner Mitochondrial Membrane 
IMS Intermembrane Space 
IPTG  Isopropyl-Beta-D-Thiogalactopyranoside  
ITC Isothermal Titration Calorimetry 
JNK c-Jun N-terminal Kinases 
LB Luria-Bertani Broth 
LC-MS  Liquid Chromatography Mass Spectrometry  
LOPAC Library of Pharmacologically Active Compounds 
MEF Mouse embryonic fibroblast 
MOMP Mitochondrial Outer Membrane Permeabilization 
MWCO  Molecular Weight Cut Off  
NADH Nicotinamide Adenine Dinucleotide Hydrogen 
NF-AT Nuclear Factor of Activated T-cells 
Ni-NTA  Nickel-NitriloTriacetic Acid  
NMDA N-Methyl-D-Aspartic Acid 
NMR Nuclear Magnetic Resonance 
NOESY  Nuclear Overhauser Effect Spectroscopy  
NTD  N-Terminal Domain  
PARP Poli ADP-ribose polymerase 
PBS  Phosphate Buffer Saline  
PCD Programmed Cell Death 
PCR  Polymerase Chain Reaction  
PD Parkinson’s Disease 
PDB Protein Data Bank 
PMSF Phenylmethanesulfonyl fluoride 
p-Na N-succinylated tetrapeptide-4-nitroanilides 
PPIase Peptidyl Prolyl cis-trans Isomerase 
PVDF  PolyVinyliDene Fluoride  
ROESY Rotating frame Overhause Effect Spectroscopy 
ROS Reactive Oxygen Species 
SARS Severe Acute Respiratory Syndrome 
SD Standard deviation 
SOD Superoxide Dismutase 
STD Saturation Transfer Difference 
TNF Tumor Necrosis Factor 
TRAIL Tumor necrosis factor-related apoptosis- inducing ligand 
WHO World Health Organization 
TFA Trifluoroacetic acid 
TFE Trifluoroethanol 
TOCSY Total Correlated Spectroscopy 
TNF Tumor Necrosis Factor 
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SUMMARY 
In this research work, we described the importance of peptides as a therapeutic approach for 
the resolution of many diseases. 
In particular, we focused our attention on the lethal role of complex protein AIF/CypA, 
involved in neuronal cell death. 
The aim of this project was the structure-based design and optimization of AIF/CypA 
peptide inhibitors, using NMR studies and combinatorial chemistry. 
The peptides were designed from AIF(370-394) peptide, mimetic of amino acidic region 
370-394 of AIF protein, able to block in vitro the proteins interaction, through its bond to 
CypA and able to induce neuroprotection. 
The identified peptides will be used to for the treatment of neurodegenerative disorders. 
 
Moreover a second project was focused on development of a simple and homogenous 
fluorescent HTS assays for the discovery of CypA cis-trans isomerase activity inhibitors, 
using a new FRET-based substrate probe useful for Chymotrypsin-coupled isomerase 
assays. 
For this purpose, we have designed a new fluorescent peptide substrate, useful to the use of 
in order to have a high proportion of cis conformers and to work by following fluorescence 
intensity increase or decrease, depending on enzyme activation or inhibition.  
The assay is helpful to screening set of large compound libraries. 
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ABSTRACT 
The AIF/CypA complex plays a key role in the mechanisms of cell death independent from 
the activation of caspases. Upon apoptotic stimuli, such as oxidative stress and hypoxia-
ischemia, AIF moves from mitochondria to nuclei, where it induces large scale DNA 
fragmentation and cell death. In some neuronal cell lines and in mouse models of ischemic 
or hypoxic brain damage, the lethal activity of AIF depends on its interaction with 
Cyclophilin A (CypA). Starting from a predicted molecular model of the AIF/CypA 
complex, a peptide mimetic of the protein region of AIF involved in the interaction with 
CypA has been selected and investigated. A synthetic peptide reproducing this region and 
corresponding to residues 370-394, is capable of inhibiting the interaction between the two 
proteins in vitro, through its binding with CypA. The peptide encompasses a protein region 
containing a β- hairpin motif which likely plays a pivotal role in CypA recognition. 
The transfection of this peptide in neuronal cells significantly blocks the glutamate-mediated 
mechanism of cell death, an effect caused by the failure of lethal complex translocation from 
mitochondria to the nucleus. These data not only confirmed the key role of the two proteins 
in inducing the neuronal death mechanism, but also indicate that molecules able to block in 
vivo the formation of this complex may represent "first-in-class" drugs for the treatment of 
cerebral ischemia and several neurological disorders. 
Given the peptide size, its poor stability in biological media and its inability to cross 
biological membranes, it cannot be readily used for therapeutic purposes. 
Thus, in the present study, using the peptide AIF(370-394) as starting template, a structure-
based approach and a combinatorial studies have been applied for the design and 
optimization of new selective inhibitors of the AIF-CypA complex. In particular, by means 
of 1H STD-NMR experiments, the AIF(370-394) residues crucial for the association with 
CypA have been identified and have been used to generate a shorter and more compact 
peptide having also an increased affinity for the target protein. Following peptide cyclization 
via a disulfide bridge and an Ala-scanning approach, a new peptide covering the region 381-
389 (hereafter AIF(381-389)ox) has been identified and submitted to further investigation. 
AIF(381-389)ox adopts a β- hairpin-like structure and shows a dose-dependent binding to 
CypA with a KD value in the μM range as AIF(370-394). CSP-NMR studies, combined with 
STD-NMR studies have been used to generate a docking model of the CypA-AIF(381-
389)ox complex, where residues from AIF(381-389)ox peptide have been included in the 
surface recognition region of AIF(370-394)/CypA. 
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To further improve the affinity of the new peptide and its propensity to adopt the β- hairpin 
conformation such as in the AIF protein, a combinatorial approach has been undertaken. 
By this approach a set of simplified peptide libraries incorporating random residues on 
peptide positions not apparently involved in the recognition with the target protein have 
been prepared and screened in a positional scanning format. 
The screening of libraries was performed using SPR-based Corning Epic label-free 
technology, and was lead to the identification of a single cyclic peptide that retained the β- 
hairpin conformation and bound CypA in the nanomolar range. 
Altogether, the data suggest that the new selected peptide is a very good structural template 
for further refining structure and activity of AIF/CypA inhibitors and the deep knowledge of 
the binding hot-spots can be exploited to design small molecules with improved 
pharmacokinetic and pharmacodynamics features. 
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1. INTRODUCTION 
1.1 Neurological disorders: the economic impact 
"Ageing is a privilege and an objective of the company. It is also a challenge, which has an 
impact on all aspects of society in the twenty-first century." 
The “World Health Organization” (WHO) proposes this message on public health, which 
indicates the importance of the phenomenon of aging: although the extension of life 
expectancy is a great achievement of modern medicine, the other side of the coin 
represented by an increase in the load of non-communicable diseases, such as cardiovascular 
disease, diabetes, cancer, Alzheimer's disease and other neurodegenerative diseases [1]. 
In particular, the report 
“Neurological disorders: Public 
health challenges” published in 
2006 from the World Health 
Organization showed that 
neurological disorders, ranging 
from epilepsy to Alzheimer 
disease, from stroke to 
headache, affect up to one 
billion people worldwide. 
Statistical data report that 
neurological disorders are an 
important cause of mortality and constitute 12% of total deaths globally, bound to increase 
over the years. Within these, cerebrovascular diseases are responsible for 85% of the deaths 
due to neurological disorders (Figure 1.1). 
The social impact of these diseases, such as Alzheimer's, is devastating, with an average 
term of 10 years, during which the patient's autonomy decreases requiring commitment and 
rising costs from the family. These patients are rarely hospitalized and more than 75% of 
treatment and careis provided by families, living the daily drama of an emergency health 
still unresolved. 
Given the impact of the disease in terms of health, social and political involvement, there are 
considerable investment in research on the pathogenesis, in outlining the causal risk factors, 
and in identifying preclinical markers in order to allowan early diagnosis, establish a 
prognosis and prepare effective treatments [1]. 
Cerebrovascular 
diseases ; 85%
Alzheimer's and 
other dementia; 
6,28%
Tetanus ; 2,83%
Meningitis; 2,24% Epilepsy; 
1,86%
Parkinson's disease; 
1,55% Multiple 
sclerosis; 0,24%
Japanase 
enchephalitis; 
0,17%
Cerebrovascular diseases 
Alzheimer's and other 
dementia
Tetanus 
Meningitis
Epilepsy
Parkinson's disease
Multiple sclerosis
Japanase enchephalitis
Figure 1.1: Deaths from selected neurological disorders as percentage of tota l 
neurological disorders
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1.2 Neuronal Cell Death mechanisms 
Neurological disorders are diseases affecting the brain and the central and autonomic 
nervous systems. They can affect an entire neurological pathway or a single neuron. Even a 
small disturbance to a neuron’s structural pathway can result in dysfunctions.  
The regulation of balance between neuronal life and death is a very delicate process, 
regulated by a constellation of trophic or proapoptotic factors [1, 2]. 
These last are responsible, by binding to specific receptors, of the activation of cell survival 
programs, growth and neuronal differentiation or conversely activation of programs that lead 
to cell self-destruction, represented by programed cell death pathways (PCD) [2].  
The above processes are required for the normal development of the central nervous system, 
as well as for the removal of dysfunctional cells in pathological conditions, but excessive 
loss of neurons is also involved in many human neurological disorders, including acute brain 
injury, neurodegenerative diseases (PD), and amyotrophic lateral sclerosis (ALS) [3]. 
A better understanding of the molecular underpinnings of neuronal death is leading directly 
to novel preventative and therapeutic approaches to neurodegenerative disorders. 
The mechanisms of cell death in several neurodegenerative diseases are often unclear; there 
are three major types of morphologically distinct cell death: necrosis, apoptosis and 
programmed cell death [4, 5, 6]. 
 
Necrosis 
Necrosis is an acute and passive form of cell death associated with the loss of ATP. 
Indeed, in hypoxic conditions, or even in ischemia, 
the reduction of oxidative phosphorylation results 
in a depletion of ATP and consequent 
malfunctioning of the ATP-dependent sodium-
potassium -pump-(Na+-K+-ATP-ase pump) [7]. 
These events initially lead to reversible 
modifications such as cell swelling with formation 
of small vesicles. 
If the process continues, there is a point of no 
return, characterized by dilation of mitochondria 
and the formation of large vesicles.  
Figure 1.2: Phases of necrotic processes
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This is followed by the lysis of cellular organelles and of the nucleus, due to the loss of the 
integrity of the membranes them selves (Figure 1.2). 
Finally, when the cell is broken, there is the release of the cytoplasmic material in the 
extracellular milieu and the activation of inflammatory response elements [7, 8]. 
 
Apoptosis 
Apoptosis describes a process of neuronal death, where the diying cells condense and fall 
off, with the support structures, in tissue on which they are growing [9].  
In the initial phase, the cell undergoes a reduction 
in cytosolic volume and then a narrowing 
(shrinkage), due to the destruction of the 
cytoskeleton.  
Later, there is a condensation of chromatin 
(pyknosis), paralleled by the nuclear disintegration 
and chromatin fragmentation [10]. 
Finally, the granules of degraded chromatin move 
to the periphery of the core reaching the plasma 
membrane, where they are surrounded by the 
evaginations membrane, giving to cells a bubble 
aspect (blebbing) (Figure 1.3).  
These bubbles are detached from the cell body constituting the so-called apoptotic bodies, 
that are engulfed by macrophages or neighboring cells [11]. Without this event there is an 
inflammatory reaction [11]. 
Apoptosis absolves an important physiological function in the replacement of senescent and 
excessive cells. In contrast to this role, pathological pathways of apoptosis have been 
associated with the progressive neuronal loss during several neuronal diseases, as well as 
with delayed cell death after acute brain damage caused by cerebral ischemia or traumatic 
brain injury [12, 13]. 
 
Programmed Cell Death (PCD) 
Programmed Cell Death (PCD) was first described in a developmental context, even before 
apoptosis, as the cell death that occurs because of a genetic clock at a predetermined time 
[14]. 
Figure 1.3: Phases of apoptotic processes
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PCD occurs in a regulated process, which usually 
confers advantage during an organism's life-cycle. 
Moreover, since the PCD is a predetermined process, 
it is potentially open to therapeutic intervention.  
Apoptosis and autophagy are both forms of 
programmed cell death, where as necrosisis is 
considered a non-physiological process that occurs as 
a result of infection or injury [15]. 
The cell death mechanisms that mediate the specific 
PCD processes include caspases and pro-apoptotic 
members of Bcl-2 family (apoptosis), JNK and ATG 
orthologs (autophagy), ERK2 (paraptosis, a cell death associated with trophotoxicity), 
PARP/AIF (PARP/AIF-dependent death), calpains/cathepsins (calcium-dependent death) 
and JNK (oncosis), among many others (Figure 1.4) [16, 17]. 
 
 
 
 
  
Figure 1.4: Molecular mechanisms of Programmed
Cell Death
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1.3 Molecular pathways involved in neuronal cell death 
Pathways involved in neuronal cell death mechanism are manifold and generally are divided 
in: caspase-dependent and caspase independent mechanisms [18]. 
Caspase-dependent pathway 
Caspases are cysteinyl aspartic acid-proteases activated by proteolytic cleavage. 
The mechanisms that produce apoptosis require caspase-mediated cleavage of specific 
substrates.  
In particular, caspase activation can happens through 
the extrinsic and intrinsic pathways [19]. 
The extrinsic signaling pathways involve 
transmembrane receptor-mediated interactions. These 
receptor families, as an example FasR, TNFR1, DR3, 
and DR4/DR5 bind to extrinsic ligands, including 
FasL, Trail, TNF-alpha, Apo3L and Apo2L 
respectively, to transduce intracellular signals that 
ultimately result in the destruction of the cell (Figure 
1.5) [20, 21]. 
 
In the intrinsic pathways, instead, a crucial role is played by the mitochondrial outer 
membrane premeabilization process (MOMP), which 
provides the release of cytochrome c in the cytosol 
where it induces activation of caspases [19]. 
The cytochrome c forms an ATP-dependent complex 
with the apoptotic protease activating factor-1 (Apaf-
1), to make a multiprotein complex called 
apoptosome, that induces caspase activation, through 
the cleavage of an effector caspase, responsible for 
cell death (Figure 1.6) [22]. 
 
 
 
 
Figure 3.1Figure 1.5: Elements of the extrinsic apoptotic pathway 
http://www.biooncology.com
Figure 1.6: Elements of the intrinsic apoptotic pathway
http://www.biooncology.com
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Caspase-independent pathway 
In caspase independent mechanisms, during oxidative stress, intracellular deregulation of 
Ca2+ concentration and DNA damage cause changes in the inner mitochondrial membrane 
(IMM) that results in an opening of the mitochondrial permeability transition (MPT) pore, 
loss of the mitochondrial transmembrane potential and release of proteins, including 
endonuclease G (Endo G), Smac/DIABLO, Omi/HtrA2 and AIF, from the mitochondrial 
intermembrane space to the cytosol and nucleous where they induce cell death [23]. 
Endo G traslocates to the nucleus where it is involved in DNA degradation, upon 
MOMP induction. It allows apoptosis to proceed even in the absence of caspase activation 
when the mitochondria are damaged [24]. 
The human protein Smac (and its 
murine orthologue DIABLO), once released, 
bind to different members of the inhibitor of 
apoptosis protein (IAP) family. 
The inhibitory effects of IAP against caspases 
are neutralized by the protein Smac, which by 
interacting with the BIR2 domain, forms a 
stable complex with the IAP, and through 
steric encumbrance, destabilizes the 
interaction between caspase and IAP favoring 
the release of the active caspases and 
proteasome degradation of IAP [25]. 
Omi is a molecule belonging to the family of serine proteases. Once released into the 
cytosol, it is capable to significantly improve the activity of caspases through direct 
proteolytic cleavage of IAPs. In addition, HtrA2/Omi can also induce apoptosis by its 
protease activity, acting independently of caspases [26, 27]. 
The Apoptosis Inducing Factor (AIF) is able to initiate the apoptotic process, 
inducing chromatin condensation and DNA fragmentation by a mechanism completely 
independent from the activation of caspases. (Figure 1.7) [28]. 
Figure 1.7: The death signal pathway through the mitochondrion
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1.4 Apoptosis Inducing Factor (AIF): structure, functions and cellular 
localization 
Apoptosis inducing factor (AIF) is a phylogenetically old flavoprotein with NADH 
oxidase activity normally contained in the mitochondrial intermembrane space (IMM). It is 
implicated in several vital and lethal cellular processes [29]. 
AIF is encoded in the nucleus and synthesized in the cytoplasm as a ~67 kDa precursor 
protein. It is imported to mitochondria by two mitochondrial localization sequences (MLS), 
that are placed within the N-terminal pro-domain of the protein.  
Upon mitochondria import, the precursor is processed to a mature form of 62 kDa by 
proteolytic cleavage of MLS sequence removed by a mitochondrial endopeptidase.  
On this configuration, AIF is an inner membrane-anchored protein whose N-terminus part is 
exposed to the mitochondrial 
matrix and whose C-terminal 
portion is exposed to the 
mitochondrial intermembrane 
space [30]. 
In this form, AIF plays a vital 
function related to the 
respiratory chain stability 
and/or to maintenance of the 
mitochondrial structure. 
The mature human form of 
AIF comprises three structural domains: an N-terminal mitochondrial localization sequence 
(MLS) of 100 aminoacids (aa), a spacer sequence (aa 101-121), a FAD-binding domain (aa 
122-262 and 400-477), a NADH-binding domain (aa 263-399) with two nuclear leading 
sequences (NLS) and a C-terminal region which consist of 136 aminoacids (Figure 1.8) 
[31]. The sites for the non covalent binding of FAD and relatively weak binding for NADH 
have been precisely mapped, and the mutants E313A and K176A have been shown to 
reduce FAD binding [32]. 
Moreover the C-terminal domain has become the most attractive part of AIF after recent 
data have confirmed the pro-apoptotic function of the this region [33]. 
The crystal structure of AIF reveals an oxidoreductase-like folding (Figure 1.9) [32]. 
Figure 1.8: Primary structure of AIF, FAD-bipartite domain (FAD; yellow),
NADH-binding domain (NADH; purple) and the C-terminal domain (red)
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Cloning of the full-length cDNAs of mouse AIF (mAIF), 612 aminoacids (aa) and human 
AIF (hAIF), 613 aa, showed that AIF is strongly 
conserved between these two mammalian species 
(92% aa identity in the whole protein) and bears a 
highly significant homology with oxidoreductases 
from all eukaryotic and prokaryotic kingdoms in its 
C-terminal portion (95% aa identity between aa 128-
612 in mAIF and hAIF) [34]. 
In vitro, AIF has been shown to have a redox 
activity accepting electrons from NADH to form 
superoxide anion [35]. 
Vital functions have been associated with the protein and have been confirmed by studies in 
the harlequin (Hq) AIF-mutant mouse, which has an 80% reduction in AIF expression. 
Such studies have suggested that this protein acts as a free radical scavenger [36]. 
Indeed ,Hq mice develop blindness, ataxia, progressive retinal and cerebellar degeneration 
due to the age-associated, progressive loss of terminally differentiated cerebellar and retinal 
neurons [37]. 
Moreover, it has been observed that hypoxia/ischemia is particularly toxic to the 
hearts of Hq mice, compared to the control hearts, and that the administration of the 
synthetic superoxide dismutase and catalase mimetic EUK8 could reduce cardiac oxidative 
stress and ameliorate the survival of Hq mice subjected to experimental constriction of the 
aorta [38]. 
Similarly, in a model of neuronal cell 
death, the intensity of oxidative stress, 
measured by lipid peroxidation and 
protein nitrosylation, in the injured area 
of the Hq brains,  increased compared 
to wild-type littermates [29]. 
Toghether with its vital functions, AIF 
is able to mediate nuclear and 
cytoplasmic effects of programmed cell 
death in response to several stimuli. 
While in healthy cells AIF is anchored 
to IMM by an amino-terminal 
Figure 1.9: Crysta llographic structure of the
human Apoptosis InducingFactor
(N- terminus= blu, C-terminus=red)
Figure 1.10: Schematic representation of AIF-mediated
caspase-independent PCD
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transmembrane segment, upon several cell death stimuli and MOMP, the 62 kDa AIF-
mitochondrial form is cleaved by activated calpains and/or cathepsins to yield a soluble 
proapoptotic protein with an apparent molecular weight of 57 kDa, denoted as truncated AIF 
(tAIF) (Figure 1.10).  
Once released from mitochondria to the cytosol, tAIF translocates to the nucleus and 
mediates chromatin condensation and degradation of DNA into ∼50-kb fragments [39]. 
Several studies have demonstred that the pro-apoptotic function of AIF is independent from 
its vital functions [40]. 
Indeed, the chemical inactivation of the FAD moiety required for AIF redox activity 
does not block its apoptogenic function in cell free systems. In a similar way, mutations that 
destroy the FAD binding site do not affect the lethal function of AIF in transfection assays 
[41]. The lethal function of AIF is 
particularly relevant in neuronal 
cells. 
Many papers have described the 
role of AIF in neuronal cell death 
in a variety of different rodent 
models of acute brain injury 
induced by cerebral hypoxia/ 
ischemia (HI), by middle cerebral 
artery occlusion, by cardiac arrest-
induced brain damage, by 
epileptic seizures or even by brain 
trauma [42]. 
Experiments in vivo, performed on Hq mice, allowed confirmation of the neuro-
lethal AIF activity, yet suspected from in vitro observations of AIF implication in poly 
(ADP-ribose) polymerase I (PARP1)-mediated neuronal death (Figure 1.11) [43]. 
The mechanism by which the PAR polymer causes AIF release is not known. However due 
to its highly charged nature, it could conceivably depolarize mitochondria leading to 
permeability transition and subsequent AIF release [44]. 
Moreover, in vivo excitotoxic studies using kainic acid-induced seizures revealed that the 
brains of Hq mice developed less hippocampal damage than wild-type animals. 
Accordingly, cortical neurons isolated from Hq mice are less susceptible to the exitotoxicity 
induced by glutamate, NMDA or kainic acid [33, 45]. In addition, compared with wild-type 
Figure 1.11: AIF-mediated cell death pathway. The
excessive activation of poly ADP-ribose polymerase
(PARP) sends the nuclear signal to the mitochondrion,
triggering AIF release from the mitochondrion to the
nucleus with chromatin condensation and DNA
fragmentation
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animals, the brains of Hq mice are more resistant to ischemia-induced damage [29, 46]. 
A decrease in AIF levels protects primary neurons against glutamate, NMDA or 
hypoxia/hypoglycemia-induced death [46, 47, 48]. 
Another factor inducing neuroprotection is the inhibition of AIF translocation from 
the mitochondrion to the nucleus; indeed the prevention of the mitochondrial membrane 
permeability transition obstructs AIF translocation and cell death in a rat model of 
hypoglycemia-induced brain damage [49]. 
Furthermore, it has been demonstrated that also the overexpression of the chaperon HSP70, 
which binds to AIF and impedes its nuclear translocation [50], has a neuroprotective effect 
in a transgenic mouse model of hypoxia/ischemia [51].  
Replacement of endogenous AIF by AIF mutants that cannot be either released from 
mitochondria or cannot translocate to the nucleus, improves the survival of AIF-deficient 
neurons that are treated with the otherwise lethal topoisomerase inhibitor camptothecin [52]. 
All evidences reported in the literature demonstrate the crucial role of AIF neuronal cell 
death mediated by a caspase-independent mechanism. 
Recently, it has been demonstrated that in some neuronal models either in vitro and 
in vivo, the lethal action of AIF is directly dependent on the interaction with the cytosolic 
protein Cyclophilin A (CypA) [53, 54]. 
20 
 
1.5 Cyclophilin A (CypA): structure, functions and cellular localization. 
Cyclophilins (CyPs) are a family of ubiquitous proteins, evolutionarily present in all 
prokaryotes and eukaryotes, involved in a variety of functions related to cell metabolism and 
energy homeostasis [55]. Human CyPs family consists of 16 members, that are structurally 
distinct: 7 major cyclophilin isoforms in humans include CypA (also called hCyp-18a, 
where 18 denotes a molecular mass of 18 kDa), hCypB (also called hCyp-22, 22 kDa), 
hCypC, hCypD, hCypE, hCyp40 (40 kDa) and hCypNK (first identified from human natural 
killer cells) [56]. 
The existence of tissue and organelle specific isoforms, moreover, explains the diversity of 
pathways in which CyPs are involved. 
The 18-kDa archetypal cyclophilin (CypA) is a cytosolic protein found in all tissues, and 
representing up to 0.1-0.6 % of the total cytosolic 
proteins. 
CypA, also called Peptidyl-prolyl-Isomerase A, was 
originally characterized for its ability to catalyze the 
transition between cis- and trans- proline residues 
critical for proper folding of proteins. This protein is 
able to regulate protein folding and modify their 
molecular conformation [57]. 
The crystallographic structure of CypA [58, 
59] reveals an eight-stranded antiparallel-barrel, 
with two helices enclosing the barrel from either side. Seven aromatic and other 
hydrophobic residues form a compact hydrophobic core within the barrel, usually in the area 
where Cyclosporin A (CsA) binds (Figure 1.12). 
Indeed, CypA is known as the primary intracellular receptor of this immunosuppressive 
drug. Once formed, the complex between CsA and CypA, binds and inhibits calcineurin, a 
calcium-calmodulin-dependent phosphatase, resulting in different biological consequences 
depending on cell type. Firstly it provokes the block of the immune response against 
transplants. Indeed, when calcineurin is inhibited, it no longer dephosphorylates nuclear 
factor of activated T cells (NF-AT), which remains in its phosphorylated (inactive) form in 
the cytosol. The failed translocation of NF-AT to the nucleus prevents the activation of 
genes transcription encoding cytokines, such as interleukin-2, and thus of the immune 
response against transplants [60]. 
Figure 1.12: The structure of complex
between the drug Cyclosporin A (CsA) and
human Cyclophilin A (CypA)
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Moreover, besides its involvement in the processes of immune diseases, CypA can be 
secreted into the extracellular environment in various cell types due to inflammatory stimuli 
such as infection, hypoxia, and oxidative stress [61]. 
Several studies have demostrated the increased levels of soluble extracellular CyPA in 
patients with inflammatory responses such as in serum of patients with sepsis [62], in 
patients with asthma [63], and in plasma of patients with coronary artery disease [64]. 
In this regard, CypA is a critical molecular biomarker in the early pathogenesis of essential 
hypertension and in related cardiovascular disorders [64]. 
Therefore, CyPA is involved in diverse pathological processes of cancer 
development: it promotes cancer proliferation [65], regulates cell cycle progression [66], 
blocks apoptosis [67], and promotes cell migration/invasion [68]. 
Even more prominent appears to be the role of CypA in neurodegenerative diseases, indeed 
in brain tissue, its expression is particularly high. It is present mainly in the cytoplasm but 
can also be found in the nucleus [69]. 
The involvement of this protein in neurodegenerative diseases and in disorders caused by 
oxidative stress was identified a long time ago [55, 58, 70]. 
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1.6 CypA and AIF in neurodegenerative diseases 
In pathways of programmed cell death in neurons, the interaction of the cytosolic 
CypA and mitochondrial protein AIF, plays a key role, in vitro and in vivo [71]. 
However, the mechanism at the basis of the lethal action of the complex AIF/CypA is still 
not clear. 
Two different models of action have been proposed: one proposes that the lethal 
translocation of AIF to the nucleus requires its interaction with CypA in the cytosol [72], 
while in the other it is proposed that AIF and CypA independently translocate to the nucleus, 
where they regulate chromatinolysis and programmed necrosis by generating an active DNA 
degrading complex involving the H2AX protein [73]. 
In support of the first hypothesis, it has been reported that the nuclear translocation of AIF is 
significantly reduced in a model of perinatal HI in CypA−/− mice compared with wild-type 
mice. Further, in AIF-deficient mice carrying the Hq mutation, CypA staining in the nucleus 
is reduced after injury and this correlates well with the protective effects in models of 
cerebral ischemia.[72]. 
In the second model, experimental data have shown the separate traslocation of the two 
proteins in the nucleus, underlying that the downregulation of CypA in MEF cells does not 
arrest nuclear translocation of AIF, but reduces DNA damage [73]. 
These controversial data suggest that the molecular events associated with caspase-
independent cell death can depend on the cell type and the kind of apoptotic stimulus [71]. 
Recently, the group where I have performed the work of my PhD thesis, has 
demonstrated that the pharmacological inhibition of the AIF/CypA complex in neuronal 
cells is a very effective approach, not only to block neural loss, but at the same time to 
restore cell viability. 
In particular, starting from the molecular model of the complex between AIF and CypA 
[72], we designed AIF peptides targeting the AIF-binding site on CypA. The peptide able to 
inhibit the interaction between AIF and CypA was identified by in vitro assays and the 
neuroprotective potential of such complex inhibitor was explored in living cells using a 
model of glutamate toxicity in immortalized mouse hippocampal HT-22 neurons [71]. 
This cell line lacks ionotropic glutamate receptors and glutamate-induced death is mediated 
by inhibition of the cellular cystine import, subsequent glutathione depletion and enhanced 
lipoxygenation, inducing a form of programmed cell death mostly due to AIF lethal nuclear 
translocation [74]. 
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We provided evidences that the delivery of the peptide, that encompassed the region 
370-394 of protein AIF, called AIF(370-394) peptide, induces neuroprotection by inhibiting 
the AIF-CypA axis. 
These findings are supported by several evidences: (i) first, similar to the down-regulation of 
CypA the delivery of the peptide AIF(370-394) drastically reduces the sensitivity of 
glutamate-mediated oxidative stress in neuronal cell lines; (ii) AIF(370-394) blocks the 
nuclear translocation of AIF and CypA, the key event in the caspase-independent cell death 
mechanisms; (iii) the active peptide provides protection against glutamate-mediated 
mitochondrial dysfunctions and reduces the sustained rise in intracellular Ca2+ [71]. 
The oxidative stress is an important factor contributing to delayed neuronal death after acute 
brain injury by cerebral ischemia or brain trauma, and in neurodegenerative diseases, such 
as Parkinson’s disease and Alzheimer’s disease. As mentioned, the pathogenesis of 
neurodegenerative disorders is induced by multiple factors, such as Ca2+ overload, ROS 
production and mitochondrial dysfunction [75, 76]. 
Therefore, multitarget strategies are necessary for inducing neuroprotection or for the 
treatment of neurodegenerative diseases. 
We demonstrated that inhibitory compounds targeting CypA, and perspectively AIF, can 
work as multitargeted neuroprotectants without apparent toxicity effects, and can therefore 
display advantageous pharmacological profiles. 
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1.7 Peptides as theraupeutical drugs 
Recently the growth in knowledge of the pathogenesis of neurodegenerative diseases has led 
to the discovery of new target molecules capable to reduce the symptoms, but hardly the 
causes. Among many others, therapies based on the use of peptides have been proposed to 
restore proper protein mechanisms, to counteract oxidative stress and to correct protein 
misfolding [77]. 
Useful strategies to identify 
potentially therapeutic peptides are 
based on the rational design and on 
combinatorial chemistry.  
The rational design of peptides is 
mostly based on the knowledges of 
structural information on a single 
protein or on protein-protein 
complexes involved in the 
development of pathological conditions.  
More specifically, the rational design of a peptide inhibitor is based on an alternate process 
of design-synthesis and testing of molecules complementary in shape to the biomolecular 
target they will potentially bind [77]. 
Conversely, in absence of structural informations, combinatorial approaches can be used to 
generate and screen peptides binding target proteins (Figure 1.13). 
Through combinatorial chemistry, a large number of structurally related peptides is 
synthesized and is then tested using a screening assay to identify the more active [78, 79]. 
Once a promising molecule (or lead coumpound) is identified, the affinity for the target can 
be matured affinity by progressive structural changes and testing. 
When a sufficiently potent compound is identified, the peptide generally undergoes a 
process of “depeptidization” to enhance stability, uptake and delivery [80]. 
  
Figure 1.13: Development and Production of a peptide
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2. AIMS OF THE PROJECT 
This research project is focused on the study of the molecular recognition between 
Cyclophilin A (CypA) and Apoptosis Inducing Factor (AIF), proteins involved in neuronal 
cell death mechanisms. 
Previous studies have shown that the region of AIF spanning residues 370-394 mediates the 
interaction with CypA, and promotes neuronal death. The corresponding synthetic peptide 
does block the interaction between AIF and CypA and is able to inhibit cell death.  
In the present study, using the peptide AIF(370-394) as starting template, we have 
undertaken a structure-based approach design new optimized and more selective inhibitors 
of the AIF-CypA complex. 
A combined approach based on both rational drug design and combinatorial chemistry has 
been applied to obtain peptides with improved pharmacodynamic features. 
1H Saturation Transfer Difference NMR experiments have guided the rationale for 
restricting the template to a shorter peptide, while a screening of combinatorial libraries in a 
positional scanning format allowed the identification of residues essential for the interaction 
with CypA. Binding peptides have been identified by ITC and SPR-based Corning® Epic® 
label-free technology using an Enspire (Perkin Elmer) instrument. 
Peptides with IC50s in the micromolar range have been identified and characterized. 
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3. MATERIALS AND METHODS 
3.1 Substrates and Chemicals 
Oligonucleotide primers for PCR were purchased from Sigma-Aldrich (Milan); DNA 
extraction and purification kits were from Qiagen (Germany), Phusion polymerase 
(Finnzymes, Milan); expression vectors pET14b and pGEX4T3 were kindly provided by the 
Protein Expression and Purification Core Facility, EMBL (Heidelberg); the DNA molecular 
marker and the restriction enzymes were from New England Biolabs (Milan). GSTrap, 
HisTrapHP, Superdex 75 10/300 were from GE Healthcare (Milan). Bacterial expression 
strains were from Novagen, whilst the cloning strain TOP10F’ was from Invitrogen (Milan). 
The prestained protein molecular marker was purchased from Bio-Rad (Milan). Protected 
amino acids, coupling agents (HATU) and Fmoc-Rink Amide AM Resin used for peptide 
synthesis were purchased from IRIS Biotech GmbH (Marktrewitz, DE). Solvents for peptide 
synthesis and purification, including acetonitrile (CH3CN), dimethylformamide (DMF), 
trifluoroaceticacid (TFA) and methanol (CH3OH) were purchased from ROMIL (Dublin, 
Ireland). Other products such as Sym-collidine, DIPEA, Piperidine, were from Sigma-
Aldrich (Milan, Italy). Analytical HPLC analyses were performed on an Alliance HT 
WATERS 2795 system, equipped with a PDA WATERS detector 2996. Preparative 
purifications were carried out on a WATERS 2545 preparative system (Waters, Milan, Italy) 
fitted out with a WATERS 2489 UV/Visible detector. LC-MS analyses were performed 
using a ESI Ion Trap HCT ETD II Ultra PTM discovery mass spectrometer (Bruker) 
coupled with an HPLC System Alliance e2695 separation module fitted out with a 2998 
PDA detector (Waters, Milan). An EnSpire Multimode Plate Reader (Perkin Elmer) was 
used to perform label-free direct binding assays. 
 
3.2 Construction of recombinant plasmids 
3.2.1 Human CypA cloning strategy in pET-14b 
Human CypA (CypA) was cloned in pET-14b in order to obtain the protein with a tag of 
poly histidine at N-terminus. Firstly, the cypA gene was amplified by PCR from genomic 
DNA. 
The amplification was performed by using the following couples of primers: cypAFw 5’-
TATACTCGAGATTAGAGCTGTCCACAGTC-3’ and cypARev 5’-TAGAAGACA 
TCATGGTCAACCCCACCGTG-3’. The forward primers contained the XhoI restriction 
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site, while the reverse primers were designed with the BbsI restriction site and a stop codon. 
All amplification reactions were performed in a final volume of 50 μL, using 50 ng of 
template DNA. The reaction mixture contained the specific primers (0.25 μM each), dNTPs 
(0.25 mM each) and the Phusion polymerase (5U) with its buffer 1x. PCR was performed 
using a Bio-Rad apparatus, following the procedure indicated in Table 3.1. 
 
Step Procedure Time and 
Temperature 
1 Initial denaturation 3 min at 95°C 
2 Denaturation 1 min at 95°C 
3 Annealing 1 min  at 56°C 
4 Elongation for 25 cycle (from Step 2) 1 min at 72°C 
5 Elongation 10 min at 72 °C 
Table 3.1: PCR conditions 
All amplification products were analyzed by 1% agarose (Euroclone) gel electrophoresis 
performed in TAE buffer (18.6 g/L EDTA, 242 g/L Tris base. Acetic acid added until pH 
7.8). PCR products were purified by using the QIAquick PCR Purification Kit (Qiagen), and 
digested with BbsI (20 U/μL) and XhoI (20 U/μL) restriction enzymes. Each amplified 
fragment (1μg) was digested with 4 U of restriction enzymes for 3 h at 37ºC in a buffer 
containing 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT pH 7.9, 
supplemented with BSA 100 μg/mL. 
Following digestion, each fragment was cloned into the corresponding sites of the pET-14b 
expression vector, downstream to the His-tag sequence. For this purpose, the expression 
vector was previously digested with the same restriction enzymes (4 U/μg), and treated with 
calf intestine phosphatase (CIP, 10 U) (NEB) for 30 min at 37ºC. The CIP enzyme (10 
U/μL) was then inactivated at 75°C for 10 min at 1:3 molar ratio (vector/insert). 
The T4 DNA Ligase was used for ligation reactions. The reactions were performed using 20 
U/μg DNA of the T4 DNA Ligase (400 U/μL), in a final volume of 10 μL, for 3h at RT. E. 
coli TOPF’10 strain was used for cloning. 
 
3.2.2 Human CypA cloning strategy in pGEX-4T3 
Human CypA (CypA) was cloned in pGEX-4T-3 in order to produce CypA as GST-fusion 
protein. For this purpose, the cypA gene was amplified by PCR from genomic DNA. 
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The amplification was performed by using the following couples of primers: cypAFw 5’-
GGATCCTCCAGCAAGTATATAGCATGGCC-3’ and cypARev 5’-GAATTCGCA 
GATCGTCAGTCAGTCACGAT-3’. The forward primers contained the BamHI restriction 
site, while the reverse primers were designed with the XhoI restriction site and a stop codon. 
The cloning strategy was continued as previously reported. 
 
3.3 Large-scale expression 
The constructs pET14b-CypA and pGEX-4T3-CypA were transformed in E.coli to 
overexpress the corresponding recombinant proteins. Pilot expression trials were conducted 
to screen different strains in order to assess the best expression of soluble protein. 
We investigated also different growing conditions, including different IPTG concentrations, 
times and temperatures of growth. Both constructs showed optimal expression levels in the 
BL21(DE3)strain. Optimal expression conditions obtained are reported in Table 3.2. 
 
 
 
 
 
 
 
 
Table 3.2:Optimal expression conditions 
Single clones of E. coli strain, previously transformed with each recombinant expression 
vector and grown at 37 ºC on LB agar containing the appropriate antibiotic, were inoculated 
into 10 mL of LB medium, containing the same antibiotic. 
The overnight cultures were inoculated into 1L of pre-warmed LB medium. 
Cultures were grown at 37°C under shaking until they reached the mid-log phase (OD600= 
0.7÷0.8nm); then, they were induced with the optimal IPTG concentration. After the cells 
were harvested by centrifugation (6000 rpm, 30 min, 4°C). 
Cell pellets were resuspended in a lysis buffer containing 20 mM Tris/HCl pH 8.0, 150 mM 
NaCl, 0.1 mM DTT, 1mM PMSF, 0.1 mg/mL lysozyme and 0.1 mg/mL DNase and protease 
inhibitors.  
The suspension was sonicated for 40 min by using a MisonixSonicator 3000 apparatus with 
 His6tagged-CypA Gst-CypA 
OD600nm 1 0.8 
IPTG 
(final concentration) 
1mM 0.1mM 
Time 3h 16h 
Temperature 37°C 22°C 
Antibiotic Ampicillin Ampicillin 
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a micro tip probe and an impulse output of 1.5/2 (9/12 Watt). 
Bacterial lysates were then centrifuged (17500 rpm, 30 min, 4°C) and the supernatant 
(soluble fraction) was collected and analyzed by SDS-PAGE to assess the presence of 
recombinant products of interest. 
 
3.4 Purification of His6tagged-CypA 
The lysates containing tagged recombinant protein was subjected to affinity chromatography 
onto His-Trap column (5ml) connected to an AKTA-FPLC system (GE Healthcare 
BioScience AB, Uppsala, Sweden).  
Before loading the lysate, the resin was extensively washed with water and then equilibrated 
in buffer A (20 mM Tris/HCl pH 8.0, 150 mM NaCl, 0.1 mM DTT). 
Flow-through containing all unbound proteins was collected and the resin was washed with 
buffer A. The bound proteins were eluted using an imidazole step gradient from 0 to 500 
mM. Finally the His6tagged-CypA was eluted at 100 mM imidazole. 
Relevant fractions (flow-through, washes and elutions) were analyzed on SDS–PAGE gel 
and stained with Coomassie Brilliant Blue G-250 (BioRad). 
The protein migrated as a protein of ~20 KDa compatible with the theoretical MW of 
His6tagged-CypA. Pools of interest were dialyzed in buffer A (16h at 4°C) to remove 
imidazole by using membranes (Thermo) with the appropriate cut-off of 3500 Da. 
 
3.5.Purification of GST-CypA 
The column used to purify the bacterial lysates of pGEX-4T3-CypA was GSTrap affinity 
column (1 ml) connected to an AKTA-FPLC system. 
The purification method is based on the high affinity of GST for glutathione. As above, 
flow-through containing all unbound proteins were collected and the resin was washed with 
buffer A. Finally the GST-tagged-CypA was eluted with a single step of 10 mM reduced 
glutathione. Indeed, the protein migrated as a protein of ~44 KDa compatible with the 
theoretical MW of GST-CypA. 
Collected fractions were checked on SDS-PAGE and pools of interest were dialyzed in 
buffer A (16h at 4°C) to remove reduced glutathione by using membranes with a cut-off of 
10000 Da (Thermo). 
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3.6 Size Exclusion Chromatography 
Size exclusion chromatography was performed to purify all recombinant proteins, removing 
aggregates and contaminants. Purifications were carried-out at a flow rate of 0.5 ml/min 
onto a Superdex 75 10/300. The column was connected to AKTA Purifier system, using 20 
mM Tris/HCl pH 8.0, 150 mM NaCl and 0.1mM DTT as running buffer. 
Molecular weight standards from GE-Healthcare were used to calibrate the columns. 
Standards were: blue dextran (Mr 2,000,000), bovine serum albumin (Mr 66,399), 
ovalbumin (Mr 45,000), carbonic anhydrase (Mr 29,000), cytochrome c (Mr 12,000).  
Pools of interest were concentrated on appropriate Amicon-Ultra membranes (Millipore). 
 
3.7 Determination of protein and peptide concentrations 
Protein concentration was determined according to the Bradford’s method [81]. The 
Coomassie Brilliant (Bio-Rad) reagent was added to the samples and the absorbance at 595 
nm was monitored. A solution of BSA was used as standard. Moreover, protein 
concentrations were determined by reading the absorbance at 280 nm in combination with 
the theoretical molar extinction coefficient (8730 M−1cm−1) by NanoDrop200c UV-Vis 
spectrophotometer (Thermo Scientific).  
The peptides concentration, lacking tryptophan and tyrosine residues, was determined via 
the Scopes method [82], in which the absorbance of the peptide bond is monitored at 205 
nm by NanoDrop200c UV-Vis spectrophotometer. 
 
3.8 Electrophoretic analysis of proteins (SDS-PAGE) 
Electrophoresis characterizations for CypA on 15% polyacrylamide gel in denaturing 
conditions were performed according to Laemmli’s protocol [83].  
Samples were denatured at 100°C for 5 min in Laemmli Sample Buffer (Bio-Rad) with 10% 
β-mercaptoethanol. Samples were then loaded on a polyacrylamide gel and the 
electrophoresis was performed in 0.025 M Tris/HCl, 0.2 M glycine pH 8.3 and 0.1% SDS, at 
30 mA for ~1 h in Tris/Glycine/SDS Buffer for SDS application (Bio-Rad). 
Proteins were then revealed by Coomassie Brilliant-Blue (Bio-Rad) staining; gels were 
submerged in the staining solution (0.1% Coomassie Brilliant-Blue G-250, 0.1% 
hydrochloric acid (J.T. Baker)) for 30 min under gentle agitation. 
The gel was washed three times in deionized water, warmed in a microwave to remove the 
excess of Coomassie and then preserved in deionized water. 
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3.9 Mass spectrometryand trypsin digestion 
LC-MS spectra was recorded to confirm the identity of CypA. Experiments were performed 
using a 10 cm EASY-Column, ID 100µm, 5µm particle size, C18-A1 (Thermo Scientific), 
equipped with a 2 cmpre-column having an ID of 100 µm, 5 µm particle size, 120 Å, 
ReproSil-Pur C18-AQ (Thermo Scientific). Data were collected on an Ion Trap mass 
spectrometer ETD II (Bruker Daltonics) equipped with a nanoESI ion source. Most runs 
were performed at 600 nL/min, applying a linear gradient of 0.1% formic acid (FA) in 
CH3CN over 0.1% FA in H2O from 0% to 60% in 45 min.  
To characterize the protein primary structure, trypsin digestions were performed in 20 mM 
Tris-HCl, 150 mM NaCl pH 8.0.  
Proteins were digested using a trypsin: protein molar ratio of 1:50 or 1:100. The reaction 
was allowed to proceed at 37°C and resulting peptides were analyzed at different time points 
(1, 2, 3, 4 h) by LC-MS, using an EASY-Column, 10 cm, ID75 µm, 3 µm, C18-A2 (Thermo 
Scientific). 
 
3.10 Circular dichroism spectroscopy (CD) 
Jasco J-715 spectropolarimeter, equipped with a PTC-423S/15 Peltier temperature 
controller, was used to register far-UV circular dichroism spectra of CypA, in a 0.1 cm 
quartz cells. The parameters used to acquire spectra were: far UV range 190-260 nm, band 
width of 1 nm, response of 8 sec, data pitch of 0.2 nm and scanning speed of 10 nm/min. 
Spectra were recorded at 20°C, on protein solutions at 15 μM in 20 mM phosphate buffer 
pH 7.4.  
CD data were expressed as mean residue ellipticity (θ). Spectra processing was achieved by 
using the Spectra Manager software, while the analysis of the secondary structure content of 
the proteins was performed with the neural network program: CDNN [84]. 
Peptide CD spectra were registered in 20 mM phosphate buffer pH 7.4 at 25 °C in the far 
UV region from 190 to 260 nm in 0.1 cm path-length quartz cuvettes. 
Each spectrum was obtained averaging three scans, subtracting the contribution from 
corresponding blanks and converting the signal to mean residue ellipticity in units of deg × 
cm2 × dmol-1 × res-1.  
The concentration of peptides was kept at 80 μM and spectra were acquired in different 
buffers (see “Results” for details). 
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3.11 Peptides synthesis and purification 
The wild type peptide, called AIF(370-394), corresponding to the protein sequence 370-394 
(QSVGVSSGKLLIKLKDGRKVETDHI) of the AIF protein was synthesized on solid 
phase, following the Fmoc (N-9-Fluorenylmethyloxycarbonyl) methodology [85]. 
Solid phase peptide syntheses were performed using a Rink amide resin (substitution 0.5 
mmol/g) to afford a C-terminal amide sequence. 
The coupling reactions were carried out with a four-fold excess of amino acid using a 
double coupling procedure: first coupling was carried out using Oxime Pure [86] and DIC 
(Diisopropylcarbodiimide), the second one was performed using 1-hydroxybenzotriazole 
(HOBt), 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) [87] and Collidine in DMF (N,N-dimethylformamide) as 
coupling reagents. Each coupling reaction was carried out for 30 minutes at room 
temperature. 
However, the derivatives peptides from AIF(370-394), were synthesized by performing the 
coupling reactions with a four-fold excess of HATU, 4 equivalents of Fmoc-protected amino 
acids, HOBt and Collidine (relative to the synthesis scale), in DMF for a reaction time of 45 
min under continuous mixing. 
The deprotection step to remove the Fmoc group was performed firstly with 40% piperidine 
in DMF for 5 min, then with 20% piperidine in DMF for 10 min. 
All peptides, except AIF(370-394) peptide, were acetylated at N-terminus by using a 
solution of acetic anhydride/DIEA 30%/5% in DMF. Crude materials were cleaved from the 
resin by treatment with trifluoroacetic acid (TFA)/H2O/triisopropylsilane (TIS) (95:2.5:2.5: 
v/v/v) at room temperature for 3 h. The resin was finally filtered, and the peptide 
precipitated using cold diethyl ether. 
Peptides were purified using an Onyx monolithic semi-PREP C18 column (100x10mm, 
Phenomenex, Castel Maggiore, Italy) operated at a flow rate of 15 mL/min; H2O+0.1% TFA 
(solvent A) and CH3CN+0.1% TFA (solvent B) were used as eluents, using a linear gradient 
of solvent B from 0 to 70% in 20 min. Purity and identity of peptides were assessed by 
analytical RP-HPLC and LC-MS (liquid chromatography mass spectrometry).  
The peptides were cyclized dissolving the linear peptides with cysteines at N- and C-termini 
at a concentration of 10–3 to 10–4 M, in 0.015 M ammonium carbonate pH 8.0 for 24 h under 
agitation, at room temperature. Reactions were monitored by analytical HPLC and at the 
end, after acidification with trifluoroacetic acid (TFA), they were lyophilized and directly 
used for preparative HPLC purification. 
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3.12 Alanine-scanning strategy 
Alanine scanning peptides [88] were prepared by the solid phase method on a 50 μmol scale, 
using standard Fmoc-derivatized amino acids [85]. Briefly, synthesis were performed on a 
fully automated multichannel peptide synthesizer Syro I (Multisynthech, Germany). RINK 
AMIDE resin (substitution 0.5 mmol/g) was used as solid support. The coupling reactions 
were carried out as previously reported. 
The deprotection step to remove the Fmoc group was performed firstly with 40% piperidine 
in DMF for 5 min, then with 20% piperidine in DMF for 10 min. 
Peptides were removed from the resin by treatment with a TFA:TIS:H2O (90:5:5, v/v/v) 
mixture, then they were precipitated in cold diethylether and lyophilized.  
Peptides were cyclized and purified by preparative RP-HPLC using a linear gradient of 
solvent B from 10 to 45% in 8 min at a flow rate of 15 mL/min. 
Purity and identity of the peptides were assessed by analytical RP-HPLC and LC-MS. 
 
3.13 Positional scanning strategy 
Positional scanning libraries [89] were prepared by the solid phase method, using RINK 
AMIDE resin as solid support. Syntheses were performed on a fully automated multichannel 
peptide synthesizer Syro I as described in the previous section.  
Randomized positions were obtained by using equimolar mixtures of 7 building blocks 
employing a 100-fold excess of each amino acid. 
After the test of binding carried out with Label-free Corning Epic technology [90], the best 
library was screened, synthesizing each peptide present in the 7-member peptide library. 
Peptides were purified by preparative RP-HPLC using a linear gradient of solvent B from 10 
to 45% in 8 min at a flow rate of 15 mL/min. 
 
3.14 Isothermal Titration Calorimetry (ITC) 
ITC experiments were performed at 25°C using a MicroCal ITC 200 (GE Healthcare Bio-
Sciences AB, Sweden) following the standard procedure. 
The protein and peptide samples were dialyzed in phosphate saline buffer (PBS) with 1 mM 
DTT, pH 7.4. In each titration, 20 injections of 2 μL each of AIF(370-394) at 0.7 mM 
peptide were added to a sample of 300 μL of CypA at 5 μM.  
Since the signal from the first injection can usually not be used for data analysis only 0.4 μl 
were added in this step and the data point was omitted. Data were analyzed using the 
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“Origin” software (MicroCal). The association constant (Ka), molar binding stoichiometry 
(n) and the binding enthalpy (ΔH), entropy (ΔS) and Gibbs free energy (ΔG) were 
determined by fitting the binding isotherm to a one-site model with MicroCal Origin7 
software. All ITC experiments were performed in triplicate. 
 
3.15 Corning Epic label-free technology 
Binding assays were performed using the Corning Epic label-free technology on the EnSpire 
Multimode Plate Reader (PerkinElmer, Rodgau, Germany) [91]. 
Label-free biochemical assays measure changes in refraction index following a binding 
event. This change is indicated by a shift in wavelength as shown in the following schematic 
Figure 3.1. The Enspire label-free system generates reproducible and high-quality 
information for protein-protein, and protein-small molecule interactions. 
Label-free responses are measured as shifts in reflected wavelength and are expressed in 
picometers (pm). 
Results were analyzed using the EnSpire label-free user interface software. 
The difference between the last baseline measurements and the maximum signal was used to 
determine the KD value. Graphs were generated using GraphPad PRISM® v5.01. 
 
 
Figure 3.1: Schematic illustration of Corning Epic label-free technology 
 
CypA immobilization on the optical biosensors was accomplished by adding 200 µg/mL 
protein in 20 mM sodium acetate, pH 5.5, using a 12-channel Thermo Scientific matrix 
multichannel equalizer pipette followed by overnight incubation at 4°C.  
The microplate was subsequently washed three times with phosphate-buffered saline (PBS 
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1X; pH 7.4) buffer. After washing, the plate was equilibrated in the assay buffer (PBS) for 3 
hours (30 µl). After incubation, a baseline reading was recorded. After another washing step, 
15 µl of various peptides were dispensed in the plate wells.  
Peptides used for the CypA assay were diluted with the assay buffer (PBS) at a working 
concentration of 300 µM (150 µM final concentration in the plate) and then further diluted 
in the assay buffer directly in a 384-well polypropylene plate for a total of twelve different 
concentrations. The final readings were taken over a period of 1 hour.  
 
3.16  Cell Culture of HT-22 and transfection 
HT-22 cells, derived from immortalized hippocampal neurons, were cultured at a density of 
10 000 cells/well in a 96-well plate (Greiner Bio-One, Frickenhausen, Germany) at 37 °C 
and 5% CO2 in Dulbecco’s modified Eagle medium (Invitrogen, Karlsruhe, Germany) with 
10% heat-inactivated calf serum and 100 U/ml penicillin, 100  μg/ml streptomycin and 2 
 mM glutamine. Peptide transient transfection was performed using the cationic lipid 
mixture Pro-Ject Protein Transfection Reagent kit according to the manufacturer’s 
instructions (Pierce, Thermo Scientific, Munich, Germany, Prod no. 89850). 
  
3.17 Induction of Apoptosis in HT-22 Cells 
Neuronal cell death was induced for 24 hours after seeding of the cells. Induction of 
apoptosis was performed by glutamate-induced toxicity. 
Glutamate-Induced Toxicity 
For inducing glutamate toxicity [92], cell growth medium was removed and replaced by 
standard cell culture medium containing glutamate (3 mM) (Sigma-Aldrich, Munich, 
Germany). Cell viability was evaluated between 14 and 16 hours later. 
 
3.18 Cell Viability Assay 
Quantification of cell viability in HT-22 cells was performed either in standard 96-well 
plates or in standard 24-well plates by the method of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide MTT (Sigma-Aldrich) reduction. The reagent was used at 0.25 
mg/ml for 1 hour. After terminating the reaction by removing the media and freezing the 
plate at −80°C for at least 1 hour, the MTT dye was dissolved in DMSO and absorbance was 
determined at 590 nm with the blank obtained at 630 nm (FluoStar OPTIMA; BMG 
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Labtech, Offenburg, Germany). Cell viability levels were determined by comparing 
absorption of treated cell samples with that of untreated control cells samples (100% cell 
viability). DMSO control was used as solvent control. For statistical analysis, experiments 
were repeated at least three times. 
 
3.19 Expression of 15N-labelled recombinant CypA for NMR studies  
A single clone of CypA strain was cultured for 16 h at 37°C in 50 ml of LB medium with 
antibiotics. The harvested cells were centrifuged for 15 min at 5000 rpm and suspended in 
10 ml of M9 medium (Table 3.3). Subsequently a spectrophotometric reading of cells was 
carried out to determine the start value of OD600 nm (generally 0.15-0.18).  
Cells were then inoculated in M9 medium, containing 15NH4Cl (Sigma Aldrich 1g/l) as the 
unique nitrogen source, and grown at 37°C. For the overexpression the cells were grown at 
37°C till the mid log phase (OD600 nm = 0.9 ± 0.5). At this point the expression was induced 
by addition of IPTG (1.0 mM). Cells were allowed to grow for further 15-16 hours at 25°C. 
After harvesting, the cells were lysed and 15N-His6tagged-CypA was purified by affinity 
chromatography on a His-trap HP column.  
 
NaCl 0.5g 
KH2PO4 7.5g 
K2HPO4 17.4g 
15NH4Cl 1g 
1 M MgSO4 1 ml 
10 mM CaCl2 10 ml 
1M thiamine 1 ml 
20% glucose 10 ml 
ddH2O 877 ml 
Antibiotic 1 ml 
Total volume 1 l 
Table 3.3: M9 medium composition 
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3.20 NMR spectroscopy 
NMR experiments were carried out at 25°C using an Inova 600 MHz spectrometer (Varian 
Inc., Palo Alto, CA, USA), equipped with a cryogenic probe optimized for 1H detection. 
NMR data were processed by the software VNMRJ 1.1.D (Varian Inc.). One-dimensional 
(1D) spectra were analyzed using ACD/NMR Processor 12.0 [ACD/NMR]; two and three-
dimensional (2D and 3D) spectra were analyzed using tools available in CARA (Computer 
Aided Resonance Assignment) software (downloaded from cara.nmr.ch) [93]. 
The one-dimensional (1D) 1H STD-NMR spectra of AIF(370-394) and AIF(381-389)ox in 
presence of GST-CypA (100:1) were acquired with 1024 scans with on-resonance 
irradiation at -0.3 ppm for selective saturation of protein resonances and off-resonance 
irradiation at 30 ppm for reference spectra.  
A train of 40 Gaussian shaped pulses of 50 ms with 1 ms delay between pulses were used, 
for a total saturation time of 2 s. 1D 1H STD spectra were obtained by internal subtraction 
of saturated spectrum from reference spectrum by phase cycling. 
For AIF(381-389)red and AIF(381-389)ox chemical shift assignment and conformational 
analysis, 1D 1H spectra were acquired with a spectral width of 7191.66 Hz, relaxation delay 
1.0 s, 7k data points for acquisition and 16k for transformation, bidimensional (2D) [1H, 
1H] total correlation spectroscopy (TOCSY) [94], double quantum filtered correlated 
spectroscopy (DQF-COSY) [95] and nuclear Overhauser effect spectroscopy (NOESY) [96] 
were acquired with 32 or 64 scans per t1 increment, with a spectral width of 6712.0 Hz 
along both t1 and t2, 2048 and 256 data points in t2 and t1, respectively, and 1.0 srecycle 
delay. Water suppression was achieved by means of a double pulsed field gradient spin echo 
(DPFGSE) sequence [97]. 
The TOCSY experiment was recorded using a DIPSI-2 mixing scheme of 70 ms with 7.7 
kHz spin-lock field strength. The NOESY spectrum was carried out with a mixing time of 
250 ms. The data were typically apodized with a square cosine window function and zero 
filled to a matrix of size 4096 and 1024 before Fourier transformation and baseline 
correction. Chemical shift assignments (Tables 4.2 and 4.3) refer to residual water resonance 
(4.75 ppm). 
To define the AIF(381-389)ox binding site on CypA by chemical shift perturbation (CSP) 
studies, the 2D 1H- 15N HSQC spectra were recorded on 15N-CypA (80 μM) in the presence 
of increasing concentrations of AIF(381-389) peptide ranging from 0 to 800 μM in PBS 
buffer, pH 5.8.  
The CSPs were quantified by the average combined chemical shift between the free form 
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and AIF(381-389) bound CypA protein using the following equation: dHNav =[((ΔδHN)2 + 
(ΔδN/5)2)/2]1/2 [98, 99, 100], where ΔδHN and ΔδN are the chemical shift variations of the 
amide proton and nitrogen resonances, respectively. 
 
3.21  Molecular Modeling 
The HADDOCK web server [101] was used to generate a model of the CypA/AIF(381-
389)ox complex. For CypA, the crystal structure available in the protein data bank was used 
for docking calculations (PDB ID:2CYH) [102].  
For AIF(381-389), the 380-390 portion was extrapolated from the the crystal structure of 
AIF protein (PDB ID: 1M6I) [103], replacing the L380 and E390 with cysteine residues. CSP 
and STD data were used to introduce active and passive residues.  
The four best cluster with negative Z-Scores were visually inspected, and solutions not 
compatible with NMR experimental data were rejected. On this basis, the best model of the 
first HADDOCK cluster was selected as representative of the CypA/AIF(381-389)ox 
complex. 
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4. RESULTS 
4.1 Biochemical characterization of AIF(370-394)/CypA complex 
In order to define the molecular basis of the recognition between AIF and CypA, I focused 
my attention on the biochemical and CD and NMR-based structural characterization of the 
complex between CypA and the AIF(370-394) peptide. For this purpose, my first aim has 
been the large scale synthesis of AIF(370-394) peptide and the production of soluble and 
highly pure CypA recombinant protein. 
 
4.1.1 Cloning, overexpression and purification of His6tagged-CypA 
Human cypA gene was cloned in pET-14b expression vector, enabling the expression 
of the protein as poly histidine tag (6His) product, containing a highly specific cleavage site 
for thrombin protease at N-terminus. 
The host strain opted for improbe expression of the recombinant protein was the BL21(DE3) 
and the purification was achieved by one step of affinity chromatography using a His-Trap 
resin. The bound proteins were eluted using an imidazole step gradient from 0 to 500 mM 
(Figure 4.1 A) and the fractions obtained were analyzed by SDS-PAGE  
The His6tagged-CypA was eluted at 100 mM imidazole, with a high purity degree.as shown 
in Figure 4.1 B. 
 
 
Figure 4.1: His6tagged-CypA purification profile. (A) Affinity chromatography profile of the His6-tagged 
CypA. (B) 15% SDS-page analysis after His-trap. Lane 1: Marker; Lane 2: flow through; Lane 3 pooled 
fraction of wash steps at 30 mM imidazole; Lanes from 4 to 6 samples eluted at 100 mM of imidazole; Lane 7 
pooled fractions eluted at 500 mM of Imidazole. 
 
The identity of the purified protein was confirmed using mass spectrometry. To this aim the 
protein of interest was digested with trypsin and fragments obtained were submitted to nano 
75 KDa
50 KDa
37 KDa
25 KDa
20 KDa
15 KDa
6His-CypA
A B 
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flow liquid-chromatography coupled to mass spectrometry (LC-MS/MS). 
Data deconvolution, using the MASCOT software [104], allowed the univocally 
identification the protein as CypA (Figure 4.2 A-D). 
 
 
Figure 4.2: Peptide mass finger printing of CypA. (A) Chromatogram profile of CypA tryptic digestion. (B) 
Mass peaks assigned to peptides. (C) Mascot’s match score. (D) CypA sequence; matched peptides are shown 
in red and correspond to a coverage sequence of 37.4%. 
 
The folding status in solution of the recombinant His6-tagged CypA was assessed by far-UV 
CD spectroscopy. 
As shown in Figure 4.3 A, the CD spectrum of the protein was dominated at 20°C and in 5 
mM phosphate buffer at pH 7.4, by the presence of a maximum at 198 nm, a minimum at 
208 nm and an absolute minimum at 222 nm [105] which are hallmarks of largely ordered 
structure, where β-strands are predominant in agreement with the crystallographic structure 
[102].  
Thermal denaturation experiments determined a temperature of melting of 50°C (Figure 4.3 
B). Moreover the spectra recorded at 20°C upon denaturation demonstrated the process is 
reversible indicating a high intrinsic stability of the protein (Figure 4.3 C). 
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Figure 4.3: Characteristic far-UV CD spectra for CypA. (B) Thermal denaturation of CypA. CD signal was 
foll one at 222 nm in the temperature range 20-90°C. (C) Overlay of spectra at 20°C (green) and at 90°C 
(blue). 
 
4.1.2 Cloning, overexpression and purification of GST-CypA 
In order to perform NMR experiments, it was necessary to prepare the GST-CypA 
recombinant protein. In particular, cypA gene was cloned in the commercial expression 
vector pGEX-4T3. The purification of the chimeric protein was achieved by a step of 
affinity chromatography using a GSTrap column resin using 10 mM of reduced glutathione 
(GSH). The pulled fraction obtained by affinity chromatography was analyzed by SDS-
PAGE (Figure 4.4 A, B). 
 
 
Figure 4.4 : Gst- CypA purification profile. (A) Affinity chromatography profile of the Gst-CypA (B) 15% 
SDS-page analysis after Gst-trap. Lane 1: Marker; Lane 2 to 4: flow through; Lanes 5 to 6 samples eluted at 10 
mM of reduced glutathione. 
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A second step of purification by a Gel filtration on a Superdex 75 10/300 provided a highly 
pure protein (> 98%), as shown on SDS-PAGE (Figure 4.5). 
 
 
Figure 4.5: 15% SDS-page analysis after size exclusion chromatography of Gst-CypA: 
Lane 1: Marker; Lane 2: empty; Lane 3: Gst-CypA. 
 
Indeed, the protein migrated as a protein of ~44 KDa compatible with the theoretical MW of 
GST-CypA. 
 
4.1.3 AIF(370-394) preparation and structural characterization 
The peptide AIF(370-394) (370QSVGVSSGKLLIKLKDGRKVETDHI394) was 
chemically synthesized using the Fmoc solid phase method [85] and purified by Reverse 
Phase (RP)-HPLC (Figure 4.6 A). Identity and purity of AIF(370-394) were assessed by 
LC-MS. (Figure 4.6 B). 
 
Figure 4.6:(A) Real time RP-HPLC chromatogram of AIF(370-394) peptide. Column: Onyx C18; eluent A: 
H2O with 0.1% TFA; eluent B: acetonitrile (ACN) with 0.1% TFA. Flow rate 0.6 mL/min. The gradient was 
from 5% to 70% eluent B in 5 minutes. (B) ESI mass spectrum of AIF(370-394) peptide. 
 
The structural characterization of the isolated AIF(370-394) peptide was initially performed 
by CD. The CD spectrum of AIF(370-394) peptide in physiological conditions (5 mM 
GST-CypA
A B
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Figure 4.8: Overlay of far-UV CD spectra in 5 mM phosphate buffer, pH 7.4 of AIF(370
increasing concentrations of TFE
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Fattorusso. Firstly, the resolution and dispersion of amide signals of the peptide was 
evaluated in different buffers, in order to choose the ideal condition.  
In particular buffers tested were: 1) Tris-HCl 20 mM and 150 mM NaCl at pH = 7.5; 2) PBS 
1X at pH = 7.4; 3) PBS 1X at pH = 5.8.  
As possible to view, in Figure 4.9, the peptide showed sharper amide resonances in PBS 
buffer at pH 5.8 compared to the other conditions tested. For this reason, this buffer was 
chosen for the subsequent studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Buffer conditions tested to choose a better resolution for NMR studies. 
 
An almost complete proton resonance assignment of AIF(370-394) was obtained using 2D 
[1H, 1H] TOCSY [94], NOESY [96] and COSY [95] spectra using the standard procedures 
[107]. 
The lack of a significant chemical shift dispersion, of long range NOEs indicated that 
AIF(370-394) was unstructured when alone in solution in agreement with CD data. 
However, several peculiarities are observed in the region 380-390. 
Specifically, sequential HN-HN NOEs characteristic of -helix- or turn-like conformation 
were observed between residues L380 and I381, G386 and R387, V389 and E390 (Figure 4.10 A). 
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Accordingly, the amide resonances of residues I381 and R387 exhibited large negative dH 
and dH values consistent with a helix- or turn-like conformation (Figure 4.10 B). 
Nevertheless, large positive dH and dH
 of E390, together with strong sequential HN-H 
NOEs between residues L380 and I381, V389 and E390, suggested that the peptide adopts a 
conformational ensemble containing also extended or -strand-like conformations in these 
regions (Figure 4.10 B).  
In addition, the dHN and dHα protons of residues K
382 and K388 showed also large positive 
shifts (Figure 4.10 B).  
 
 
Figure 4.10 (A-B): NMR analysis of AIF(370-394) in PBS at pH 5.8 and HN-HN regionof 2D [1H, 1H] NOESY 
spectra (A). Chemical shift deviation from random coil values of H and HN backbone atoms plotted as a 
function of residue number (B). Secondary structure elements as observed in the AIF crystal structure (PDB 
ID: 1M6I) and as derived from the NMR conformational analysis in TFE 30%. 
 
Overall, NMR data confirmed the elevated flexibility of AIF(370-394) peptide and the 
prevalence of disorder in aqueous solution, but highlighted a propensity of the peptide to 
adopt local secondary structure elements in the region 380-390.  
To further asses the propensity of the peptide to assume partial secondary structure 
elements, we carried out a NMR conformational analysis in presence of TFE (30%) solvent.  
Accordingly to previous CD data, the 2D [1H, 1H] NOESY spectrum in presence of 30% 
TFE contains only a slightly higher number of signals with respect to those observed in PBS 
buffer, indicating only a limited increasing of ordered conformations (Figure 4.10 C).  
This fact precluded a high-resolution structure determination. However, information on the 
conformational preferences can be obtained by dH and dH and NOE pattern analysis. 
dH and dH showed a stretch of strong negative values in the central region of the 
AIF(370-394) peptide, from K378 to L383, indicative of a helical conformation (Figure 4.10 
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D), unlikely from the AIF protein in which they adopt a -strand conformation. 
According to dH and dH values, new strong sequential HN-HN NOEs were observed in 
this region between residues I381-K382, L383-K384, D385-G386 (Figure 4.10 C). 
It is to note that possible HN-HN NOEs between K
382-L383, K384-D385 could not detected due 
to a partial or total overlap of the HNs. However, H-H (i, i+3) were observed from S
376 
until to D385, consistent with a -helix conformation. 
Negative dHs were observed for the HN, but not for the H, of the segment D
385-G386-R387, 
that in the AIF protein assumes a turn conformation (Figure 4.10 E). 
 
 
Figure 4.10 (C-E): NMR analysis of AIF(370-394) in PBS at pH 5.8 in presence of TFE 30%.HN-HN region of 
2D [1H, 1H] NOESY spectra (C). Chemical shift deviation from random coil values of H and H
N backbone 
atoms plotted as a function of residue number (D). Secondary structure elements as observed in the AIF crystal 
structure (PDB ID: 1M6I) and as derived from the NMR conformational analysis in TFE 30% (E). Arrow and 
helix indicate -strand and helical regions, respectively. 
 
On the other hand, strong positive dHs were observed for the H of K
388 and HN and H of 
E390, indicative of a propensity of these residues to adopt an extended or -strand 
conformation as in the AIF protein.  
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presence of substoichiometric amounts of CypA and/or GST-CypA. Unfortunately, the 
conformation of the peptide bound to CypA could not be determined because of the lack of a 
sufficient number of trNOEs, probably because of a slow off-rate of the peptide from the 
CypA. However, we could observe several differences in the NOESY of the peptide in the 
presence of GST-CypA (1:150 ratio) than that in the absence of the protein, for residues: 
K378, K382, L383, K384, R387, K388, E390, T391. Minor trNOE effects were also observed for 
residues: S371, V374, S375 and L380.  
 
4.3 CypA/AIF(370-394) binding studies 
The interaction between recombinant His6tagged CypA protein and the AIF(370-
394) synthetic peptide was monitored by means of Isothermal Titration Calorimetry (ITC) 
[109] and the label free techniques [91]. 
In Figure 4.12, a representative raw titration data and results of the data after integration and 
fitting with an appropriate model is shown.  
 
Figure 4.12. (A) Raw data for the titration of CypA with AIF(370-394) peptide. Each peak represents the 
differential power decrease as the sample cell temperature increases with each peptide addition, characteristic 
of an exothermic binding interaction. (B) Data is fit with a one set of single binding sites model to give the 
thermodynamic parameters shown in the inset. 
 
N=1.02± 0.023 sites
Ka= 1.67*105 ± 2.24*104 M-1
∆H= -6.2 ± 0.2 Kcal/mol/deg
∆S= 2.24 cal/mol/deg
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ITC profiles showed that the binding of the AIF(370-394) to CypA was exothermic, 
resulting in negative peaks in the plots of power versus time (Figure 4.12 A, upper panel). 
Signals well fitted with a single site binding model to determine the KD, enthalpy (ΔH) and 
entropy (ΔS) changes of the binding reaction (Figure 4.12 B, lower panel). 
Results obtained confirmed that AIF(370-394) binds CypA with a KD of about 6 M 
through a favorable contribute of entropy and enthalpy, suggesting that the AIF(370-
394)/CypA complex formation was not only driven by a large entropy gain (TΔS = 56 ± 1.5 
cal/mol) presumably due to the high degree of freedom of the peptide but also by means of 
hydrogen bonding and/or van der Waals and Coulombic interactions (ΔH = -6.2 ± 0.2 
kcal/mol). 
Moreover, the binding constant underlying the interaction between AIF(370-394) 
and CypA was determined through a new label-free technique based on Corning Epic 
technology (See Methods section, for details) [91]. 
For this experiment, CypA was immobilized at a concentration of 200 µg/ml onto the 
amino-coupling surface of the EnSpire label-free biochemical microplate biosensor. 
After washout of the unbound target and further equilibration of the biosensor, several 
concentrations of AIF(370-394) peptide were added to the immobilized CypA protein. 
The background-corrected responses were well fitted by a one-site interaction model, 
yielding a KD= 4.7 ± 0.2µM, comparable with the data previously reported (Figure 4.13) 
[71]. 
 
Figure 4.13 :Binding curve of AIF(370-394)peptide to CypA, through Label-free Corning® Epic® technology 
 
 
 
KD= 4.7 ± 0.2 μM 
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4.4 STD Experiments of AIF(370-394)/CypA complex 
To provide additional information regarding the peptide mode of binding, STD-
NMR experiments were performed. The STD-NMR technique is a method which could give 
an epitope mapping by NMR spectroscopy. 
Saturation Transfer Difference (STD)-NMR experiments have emerged as a powerful tool 
for detecting and characterizing binding of ligands to proteins and receptors [110, 111].  
In these experiments, the protein resonances are selectively saturated, and the effect is 
transferred to the bound ligand by intermolecular spin diffusion.  
Saturated resonances of the ligand in the free state are detected by subtracting the saturated 
spectrum from one without protein saturation. 
The difference in intensity due to saturation transfer constitutes an indication of binding and 
allows to identify the residues of the ligand directly involved in the interaction with the 
protein. 
Since the sensitivity of the STD experiments is dependent from the spin diffusion efficiency 
that increases with increasing molecular weight of the target protein, we decided to use 
GST-fused CypA [112]. 
A one-dimensional 1H STD difference experiment is shown in Figure 4.14 for a 
sample, with a 150:1 excess of the peptide ligand over the GST-CypA, along with a 
reference 1H spectrum.  
As can be seen, some resonances both in the aliphatic and in the amide region receive 
saturation transfer from the protein, providing a further confirm of the AIF(370-394)/CypA 
complex formation and insight on the residues directly involved in the interaction with 
CypA.  
Specifically, in the upfield region, the strongest STD signals were ascribed to the Hε, 
Hd H and H protons of K residues, the D385 H protons and the T391 H proton. 
Moreover, methyl protons of I381, V389 or L380 residues showed saturation transfer from the 
protein, even if they could not identify unambiguously due to the spectral overlap. 
In the downfield region, STD signals were observed for some HN backbone atoms. 
However, except for the HN of Leu
383, they could not be identified unambiguously. 
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Figure 4.14: STD experiments of complex AIF(370-394)/CypA: in red residues more involved in the 
interaction with CypA; in green residues that could be involved in the interaction, but that could not be 
identified unambiguously; in blue residues not involved in the interaction. 
 
Data obtained showed that several residues arranged along the sequence of the peptide seem 
to be involved in the interaction with CypA; however, in agreement with trNOESY 
experiments, most of them are included in the central region, encompassing residues 380-
390 (Figure 4.14). Thus, based on these results was synthesized a new smaller peptide, that 
cover the region 380-390, hereafter AIF(380-390). 
 
4 5 Design and characterization of a new bioactive AIF peptide 
STD-NMR analysis provided crucial information about the amino acid residues of 
the peptide AIF(370-394) involved in the interaction with CypA.  
Data indicated that many residues along the entire peptide sequence mediate the interaction 
with CypA. Most of them were arranged on the peptide central portion containing residues 
380-390. 
Notably, in the crystallographic structure of AIF this region is in a β-hairpin conformation 
[103] (Figure 4.15 A, B).  
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aa unambigously involved
aa ambigously involved
aa not involved
aa less involved
in the CypA interaction
K382/G386/D385
Q370/D392
L383
V389
R387/I381/V374
L380/L379/I394
K378/K384/
R387
V374
I394
G377/G386
HE K388/K384/K382/K378
HB D385
HG Q370
HD K/HB L
ANTIFASE
HA
HB3 K378
8.0                      7.0                                                4.0                       3.0                      2.0                       1.0                                         
ANTIFASE
d 1H / ppm
HNter
HG K/HG12 I381-394
HG2 T391
HB I381-394/HB2 K
52 
 
 
Figure 4.15: (A) Crystallographic structure of AIF protein (PDB ID: 1M6I); in green is reported the region 
AIF(370-394).(B) Zoom of the AIF(380-390) region which in the crystallographic structure shows a of β-
hairpin conformation. 
 
On the basis of these observations, we focused our attention on residues 380-390 and started 
to investigate the corresponding synthetic peptide.  
The new peptide was synthesized with two cysteine residues (Cys) at the amino- and 
carboxy-termini to potentially stabilize a β-harpin structure through a disulfide bridge [113]. 
AIF(380-390) (C380LIKLKDGRKVE390C) was synthesized and characterized in its reduced 
(linear) and oxidized (cyclic) forms (see Methods section for details). 
The structural analysis of the linear AIF(380-390)red and cyclic AIF(380-390)ox peptides 
was carried out by CD in 5 mM phosphate buffer at pH 7.4 (Figure 4.16). 
CD spectra suggested the prevalence of unstructured conformations in solution for either 
peptides. 
However, spectra demonstrated that the introduction of the disulfide bridge in the cyclic 
peptide, provided a limited but measurable increase of secondary structure, as indicated by 
the shift of the CD minimum from 198 nm to 202 nm, for AIF(380-390)ox compared to 
AIF(380-390)red. 
AIF(380-390)ox had a minimum at 198 nm and a negative value at 190 nm, suggesting the 
coexistence of several structures in which random coil conformations prevailed, as 
previously shown also for AIF(370-394). 
 
D385
G386K384
K382
L383
R387
K388
V389
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Figure 4.16: CD spectra of AIF(380-390)red and AIF(380-390)ox. 
 
These data are also in agreement with a preliminary NMR analysis of AIF(380-390) in the 
oxide state, in which the presence of different, likely conformational, states for this peptide 
was observed. 
Moreover, the complexity of the NMR spectra (data not shown) precluded a detailed NMR 
conformational analysis of this peptide. 
 
4.6 CypA/AIF(380-390) binding studies 
The affinity of both the linear and cyclic peptides for CypA was evaluated by direct-
binding assays.  
Synthetic peptides were then tested by the label-free Corning® Epic® technology (see 
Methods for details). As shown, in Figure 4.17 A and B, either variants bound CypA in a 
dose-dependent and saturable manner. 
However, by fitting the binding curves with a non-linear regression algorithm, very different 
affinity values were extrapolated. Indeed AIF(380-390)red and AIF(380-390)ox bound 
CypA with KDs of 30 ± 2μM and 3.2 ± 0.2μM, respectively, suggesting an overall higher 
affinity of the cyclic peptide. 
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Figure 4.17: (A) Binding curve of AIF(380-390)ox peptide to CypA. (B) Binding curve of AIF(380-390)ox 
peptide to CypA using the Label-free Corning® Epic® technology. 
 
All data demonstrated that reducing the size of AIF (370-394) to AIF(380-390) resulted in a 
significant loss of the peptide affinity toward CypA, however the introduction of the 
disulfide bridge restored the affinity to comparable levels, demonstrating a direct correlation 
between the structure and the function of the new peptide. 
 
4.7 Identification of crucial residues of AIF(380-390)ox involved in CypA 
recognition: Alanine-scanning approach 
In order to investigate crucial residues of AIF(380-390)ox involved in CypA 
recognition, we synthesized and analyzed Ala-scan peptides of this region [88].  
By this approach,the wild-type residues are systematically changed to alanine. 
The peptides were synthesized using the Fmoc solid phase method [85] and purified by 
Reverse Phase (RP)-HPLC (See Methods section for details).  
Sequence, theoretical and experimental MW of the peptides are reported in Table 4.1, shown 
below. 
KD= 30 ± 2µM KD= 3.2 ± 0.2µM
A B
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Table 4.1:Sequences, theoretical and experimental mass of Ala-mutated peptides. 
Their binding abilities of all peptides to CypA were evaluated through the label free 
techniques. 
For this assay, CypA was immobilized at a concentration of 200 µg/ml onto the amino-
coupling surface of the EnSpire label-free biochemical microplate biosensor and Ala 
peptides were initially tested at two different concentrations (10 and 20 µM) (Figure 4.18). 
Name Sequence Theoretical Mass 
(amu)
Experimental 
Mass (amu)
AIF(380-390)ox CLIKLKDGRKVEC 1545.87 1545.65
ALA 1 CAIKLKDGRKVEC 1503.79 1503.49
ALA 2 CLAKLKDGRKVEC 1503.79 1503.38
ALA 3 CLIALKDGRKVEC 1488.77 1488.15
ALA 4 CLIKAKDGRKVEC 1503.79 1503.22
ALA 5 CLIKLADGRKVEC 1488.77 1488.35
ALA 6 CLIKLKAGRKVEC 1501.86 1501.16
ALA 7 CLIKLKDARKVEC 1559.90
1560.22
ALA 8 CLIKLKDGAKVEC 1460.76 1460.28
ALA 9 CLIKLKDGRAVEC 1488.77 1488.32                
ALA 10 CLIKLKDGRKAEC 1517.82 1517.52
ALA 11 CLIKLKDGRKVAC 1487.83 1487.32
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Figure 4.18: Enspire binding assay to immobilized CypAof Ala-peptides at two different concentrations (10 
and 20 µM). 
 
Data shown in Figure 4.18 suggested that peptides with alanines in place of K382, K384, R387 
and K388 had lower affinity, while those having alanines replacing L380, I381, L383 and V389 
had substantially unaltered binding affinities.  
Remarkably, peptides where D385, G386 and E390 were replaced with alanine had higher 
affinity for CypA.  
Altogether data suggested that basic residues strongly influence the ability of AIF(380-
390)ox to recognize CypA.  
 
4.8 From AIF(380-390)ox to AIF(381-389)ox 
Combining NMR and an Ala-scanning approach we ended up that residues Leu380 
and E390 have a negligible effect on the binding with CypA. 
For this reason, to further simplify the peptide structure, we designed and synthesized a new 
peptide spanning residues 381-389 still constrained by a disulfide bridge connecting two 
Cys at N- and C- termini.  
The new peptide, hereafter AIF(381-389)ox, was studied by direct binding experiments to 
CypA and bound the target protein in a dose-dependent and saturable manner, showing a KD 
of 2.3 ± 0.5μM.  
The KD was comparable to that of AIF(380-390)ox, indicating that deleting the two residues 
at N- and C- termini did not affect the interaction with CypA, as previously hypothesized 
(Figure 4.19). 
10  20    10 20   10 20    10 20   10 20    10 20    10 20   10 20   10 20   10 20   10 20    10 20
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Figure 4.19: Binding curve of AIF(381-389)ox peptide to CypA. 
 
4.9 Biological effects of peptides in HT-22 cells 
Next, we investigated whether the peptide AIF(381-389)ox could antagonizes the 
detrimental effect of the AIF/CypA complex, in the model of glutamate toxicity. 
The model of cell death chosen was the neuronal HT-22 cell line. In these cells treatment 
with high concentrations of glutamate (2-7mM) induces a cell death process exclusively 
mediated by the nuclear translocation of AIF [92]. 
Then, HT-22 cells were transfected with the synthetic peptides AIF(370-394), AIF(380-
390)ox, AIF(380-390)red, AIF(381-389)ox at 50µM, using the Pro-Ject transfection kit 
(Thermo Scientific). 
Following glutamate treatment at three different concentrations (5, 6 and 7 mM for 16h), 
cell viability was assessed by the MTT assays.  
As shown in Figure 4.20, all peptides tested provided neuroprotection, however the cyclic 
peptides AIF(380-390)ox and AIF(381-389)ox provided a greater neuroprotective effect 
compared to AIF (370-394) and peptides in linear forms.  
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Figure 4.20: Neuroprotective effects of the different AIF peptides in the glutamate-induced HT-22 cellular 
model. Results obtained were showed as percentage of controls considered to be 100% and represent the mean 
±S.D. of at least four independent experiments performed in quadruplicate. 
 
4.10 NMR studies on AIF(381-389)ox and its interaction with CypA 
Since the ability of the AIF(381-389)ox to bind CypA with a comparable affinity 
than the peptide AIF (370-394), together with its greater neuroprotective effect, we 
performed a detailed NMR analysis. In particular, a conformational analysis of AIF(381-
389)ox was first carried out, then interaction studies based on the observation of both the 
peptide (STD experiments) and the CypA protein (Chemical shift perturbation analysis, 
CSP) were performed. Data NMR were used to developed a docking-model of the complex 
between CypA and AIF(381-389)ox. 
 
4.10.1 NMR conformational analysis of AIF(381-389)ox 
AIF(381-389) peptide NMR conformational analysis was performed in PBS at pH 
5.8, as for AIF(370-394) peptide, both in the reduced and in the oxidized form. Under this 
condition, the peptide resulted well soluble with sharp resonances and, especially, showed a 
single signal set for each amino acid in both forms (Figure 4.21 and 4.22).  
These results indicated that AIF(381-389) peptide exists in a homogeneous state differently 
from AIF(380-390), supporting the hypothesis that the heterogeneity observed for AIF(380-
390) is due to different salt bridge that the negatively charged carboxyl group of E390 could 
establish with the positively charged ε-amino group of the different lysine along the 
sequence. 
 Figure 4.21: 1D1H NMR spectra of AIF(381
 
Figure 4.22: 2D [1H, 1H] TOCSY 
298K. The highest spread of HN 
indicative of its structuration. 
 
Proton spin system identification and assignment of individual
389) were carried out by using a combination
spectra, [96] according to th
-389)red and AIF(381-389)ox in PBS at pH 5.8 ad 298K.
 
NMR spectra of AIF(381-389)red and AIF(381-389)ox in PBS at pH 5.8 ad 
and Hα protons is clearly visible in the spectrum of AIF(381, 389)ox, 
 resonances of both AIF(381
 of TOCSY, [94] COSY,
e standard procedures [107].  
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 [95] and NOESY 
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Proton chemical shifts for all resonances are listed in Table 4.2 and 4.3. 
 
Residue Atom name Chemical shift 
value 
Residue Atom name Chemical shift 
value 
381 ILE H 8.15 384 LYS HE3 3.02 
381 ILE HA 4.10 384 LYS HZ 7.85 
381 ILE HB 1.83 385 ASP H 8.38 
381 ILE HG12 1.50 385 ASP HA 4.58 
381 ILE HG13 1.22 385 ASP HB2 2.74 
381 ILE HG2 0.91 385 ASP HB3 2.74 
381 ILE HD1 0.90 386 GLY H 8.39 
382 LYS H 8.41 386 GLY HA3 3.95 
382 LYS HA 4.41 387 ARG H 8.10 
382 LYS HB2 1.83 387 ARG HA 4.35 
382 LYS HB3 1.77 387 ARG HB2 1.86 
382 LYS HG2 1.44 387 ARG HB3 1.86 
382 LYS HG3 1.44 387 ARG HG2 1.84 
382 LYS HD2 1.72 387 ARG HG3 1.65 
382 LYS HD3 1.72 387 ARG HD2 3.23 
382 LYS HE2 3.02 387 ARG HD3 3.23 
382 LYS HE3 3.02 387 ARG HE 7.37 
382 LYS HZ 7.71 388 LYS H 8.40 
383 LEU H 8.29 388 LYS HA 4.40 
383 LEU HA 4.41 388 LYS HB2 1.83 
383 LEU HB2 1.68 388 LYS HB3 1.77 
383 LEU HB3 1.55 388 LYS HG2 1.44 
383 LEU HG 1.63 388 LYS HG3 1.44 
383 LEU HD1 0.93 388 LYS HD2 1.70 
383 LEU HD2 0.87 388 LYS HD3 1.70 
384 LYS H 8.44 388 LYS HE2 3.02 
384 LYS HA 4.32 388 LYS HE3 3.02 
384 LYS HB2 1.84 388 LYS HZ 7.71 
384 LYS HB3 1.78 389 VAL H 8.19 
384 LYS HG2 1.44 389 VAL HA 4.12 
384 LYS HG3 1.44 389 VAL HB 2.07 
384 LYS HD2 1.70 389 VAL HG1 0.96 
384 LYS HD3 1.70 389 VAL HG2 0.96 
384 LYS HE2 3.02     
Table 4.2: 1H Chemical shift assignment (ppm) of AIF(381-389)red in PBS buffer (pH 5.8) at 298 K. 
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Residue Atom name Chemical shift 
value 
Residue Atom name Chemical shift 
value 
380 CYS H 8.37 385 ASP H 7.84 
380 CYS HA 5.14 385 ASP HA 4.48 
380 CYS HB2 3.13 385 ASP HB2 2.99 
380 CYS HB3 2.64 385 ASP HB3 2.59 
381 ILE H 8.68 386 GLY H 8.11 
381 ILE HA 4.37 386 GLY HA2 4.31 
381 ILE HB 1.84 386 GLY HA3 3.55 
381 ILE HG12 1.42 387 ARG H 7.86 
381 ILE HG13 1.15 387 ARG HA 4.22 
381 ILE HG2 0.86 387 ARG HB2 1.93 
381 ILE HD1 0.81 387 ARG HB3 1.71 
382 LYS H 8.34 387 ARG HG2 1.60 
382 LYS HA 4.77 387 ARG HG3 1.60 
382 LYS HB2 1.75 387 ARG HD2 3.22 
382 LYS HB3 1.75 387 ARG HD3 3.17 
382 LYS HG2 1.35 388 LYS H 8.40 
382 LYS HG3 1.35 388 LYS HA 5.03 
382 LYS HD2 1.62 388 LYS HB2 1.69 
382 LYS HD3 1.62 388 LYS HB3 1.67 
382 LYS HE2 2.96 388 LYS HG2 1.38 
382 LYS HE3 2.96 388 LYS HG3 1.26 
383 LEU H 8.80 388 LYS HD2 1.64 
383 LEU HA 4.51 388 LYS HD3 1.64 
383 LEU HB2 1.95 388 LYS HE2 2.94 
383 LEU HB3 1.95 388 LYS HE3 2.94 
383 LEU HG 1.63 389 VAL H 8.83 
383 LEU HD1 0.87 389 VAL HA 4.34 
383 LEU HD2 0.81 389 VAL HB 1.99 
384 LYS H 8.27 389 VAL HG1 0.90 
384 LYS HA 4.08 389 VAL HG2 0.90 
384 LYS HB2 1.85 390 CYS H 8.38 
384 LYS HB3 1.85 390 CYS HA 5.05 
384 LYS HG2 1.48 390 CYS HB2 3.13 
384 LYS HG3 1.48 390 CYS HB3 3.02 
384 LYS HD2 1.69     
384 LYS HD3 1.69     
384 LYS HE2 3.00     
384 LYS HE3 3.00     
Table 4.3: 1H Chemical shift assignment ( ppm) of AIF(381-389)ox in PBS buffer (pH 5.8) at 298 K. 
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Analysis of H and HN chemical shifts indicate that AIF(381-389)ox, differently from 
AIF(381-389)red, show significant deviations from random coil values (ΔδHα and ΔδHN) 
(Figure 4.23).  
As shown in Figure 4.23, ΔδHα and ΔδHNof AIF(381-389)ox indicated the presence 
of two β-strands consisting of residues C380-L383 and K388-C390 separated by a turn 
constituted by residues K384-R387. This folded structure was confirmed by NOEs (Figure 
4.24), indeed while AIF(381-389)red shows few and positive NOEs, typical of small and 
flexible molecules, AIF(381-389)ox exhibits a higher number and negative NOEs, 
characteristic of a more rigid structure.  
However, the number of NOEs was not sufficient to obtain a high resolution structure of this 
peptide. Further NMR experiments also in different conditions could be addressed to 
increase the number of NOE to undertake the NMR structure calculation of AIF(381-
389)ox. 
 
 
Figure 4.23: Chemical shift deviation from random coil values of HN and H backbone atoms plotted as a 
function of residue number. Derived secondary structure elements for AIF(381-389)ox are indicated above the 
plots. Cyan arrows indicate -strand regions. 
  
63 
 
 
 
Figure 4.24: 2D [1H, 1H] NOESY NMR spectra of AIF(381-389)red and AIF(381-389)ox in PBS at pH 5.8 ad 
298K. NOE > 0 are green cross-peaks, where NOE<0 are red cross-peaks. 
 
4.10.2 STD experiments of AIF(381-389)ox/CypA complex 
STD NMR experiments were performed on AIF(381-389)ox in the presence of GST-CypA, 
as for AIF(370-394). Similarly, the 1H STD spectrum showed that AIF(381-389)ox receive 
saturation transfer in the presence of the protein (Figure 4.25 A), providing a further confirm 
of the AIF(381-389)ox/CypA complex formation and insight on the residues directly 
involved in the interaction with CypA. 
In particular, the strongest STD signals were observed in the aliphatic region and were 
ascribed to the Hε and Hd protons of K382/K384/K388, the H and H of K384, the H of D385 
and the overlapped methyl protons at about 0.8 ppm of I381, L383 or V389 residues.  
These data confirmed the importance of the lysine residues in the interaction of AIF(370-
394) and AIF(370-394) derivatives according to NMR and Ala-scan experiments. 
Moreover, they indicate that K382 and K388 could interact mainly with the terminal part of the 
side-chain (i.e ionic or polar interaction mediated by the -NH2 group), while K
384 could 
establish interaction also or only with the aliphatic side-chain. 
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4.10.3 CSP studies of AIF(381-389)ox/CypA complex 
The formation of the CypA/AIF(381-389)ox complex was followed via chemical 
shift perturbations (CSP) of 15N- His6tagged-CypA backbone signals (see Material and 
Methods for details) induced by AIF(380-390)ox in the 2D 1H- 15N HSQC spectra. 
As shown in Figure 4.25 B, a number of resonances in the 2D 1H- 15N HSQC spectrum 
exhibited continuous and significant chemical shift variations upon the subsequent addition 
of the unlabeled AIF(381-389)ox peptide to 15N-His6tagged-CypA until at a molar excess of 
10–fold. 
The largest perturbations on CypA (mapped in orange red on the docking model of the 
AIF(381-389)ox/CypA complex in figure 4.25 C) occurred on the loops 4-5 (T68), 5-6 
(A101, N102, A103), and α2-7 (V127), and in the sheets 5 (S99) and 7 (V128). 
Strong perturbations were also observed in the loops 4-5 (R69, G74, K76), 5-6 (Q111) and 
α2-7 (H126). The latter were mapped in gold on the docking model in Figure 4.25 C. 
These data indicate that the binding surface of AIF(381-389)ox on CypA is consistent with 
that of AIF(370-394). 
 
4.10.4 Docking model of AIF(381-389)ox/CypA complex 
To gain insight into the binding mechanism of CypA by AIF(381-389)ox, we carried 
out molecular docking studies by HADDOCK webserver using as input CSP and STD data. 
In particular, T68, R69, G74, K76, A101, N102, A103, Q111 and H126 of CypA and K382, K384, D385, 
K388 of AIF(381-389)ox were considered as active residues. 
S99, V127 and V128 were set as passive residues for CypA, whereas they were set 
automatically for AIF(381-389)ox. Moreover, since the AIF(381-389)ox assumes a -
hairpin conformation, we used as input the structure of the 381-389 region as it is in the AIF 
crystal structure (PBD: 1M6I) [103]. 
The docking calculations generated four clusters characterized by negative Z-score and 
showing small but significant differences in the molecular recognition of CypA by AIF(381-
389)ox.  
Interestingly, the first cluster with the lowest Z-Score was also more in line with the NMR 
data (STD and CSP). 
Therefore, we selected the first model inside this cluster having the lowest binding energy 
conformation as a representative model of the AIF(381-389)ox/CypA complex (Figure 4.25 
C). In this model, the binding site of AIF(381-389)ox on CypA, adjacent to the catalytic site, 
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is constituted by the residues: T68, R69, G72, T73, G74, G75, K76, E81, K82, A101, N102, A103, 
T107, Q111.  
Importantly, almost all them show CSP effects. On the other side, AIF(381-389)ox 
establishes an extensive number of interactions with CypA, mainly hydrogen bonds, by 
means of K382, L383, K384, D385. In particular, the K382 -amino group forms two hydrogen 
bond with the A101 backbone oxygen and the Q111 amide oxygen.  
In addition, the K382 C aliphatic chain interacts with the T107 backbone oxygen with an 
unconventional hydrogen bond.  
The L383 forms with its backbone oxygen two conventional and one unconventional 
hydrogen bonds with the hydroxyl of T68, the backbone C of G74 and the backbone amide 
HN of G75.  
However, the L383 side-chain points away from the binding site of AIF(381-389)ox on 
CypA. K384 also establishes interactions by means of its backbone oxygen with H of R69 
and C of , according with STD data in which H and H resulted most saturated, 
differently from the other lysine residues.  
The K384 side-chain points in a hydrophobic groove constituted by F46, F67, T68 and K76 side-
chains. In addition, the backbone oxygen of D383 forms a hydrogen bond with a hydrogen of 
the R69 guanidinium group. 
Hydrophobic interactions were observed between the N-terminal C380 and I381 side chains 
with the A103 and K82 side chains, respectively. 
Finally, only weak hydrophobic interactions were observed between K388 and T63 side 
chains. 
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Figure 4.25: (A) Expansion of the aliphatic region of the reference 1H (red) and STD (blue) spectra of 
AIF(381-389)ox in the presence of GST-CypA (1:100). AIF(381-389)ox sequence is reported. Residues 
showing the strongest STD effects are highlighted in red. (B) Superposition of a 2D [1H, 15N] HSQC section of 
CypA in the absence (blue) and in the presence of AIF(381-389)ox 1:5 (red), 1:10 (green). Bar graphs of the 
average combined chemical shift differences (HNav) as a function of residue number. Residueswith the 
strongest CSP are indicated. (C) AIF(381-389)ox binding mode on CypA surface as derived by docking 
studies. CypA residues most affected by peptide binding are colored, as obtained by CSP studies, in orange red  
(HNav > mean+SD ) and in gold (HNav > mean) on the surface of CypA (PDB ID: 3K0N). AIF(381-
389)ox is represented as ribbon drawing, with the side chains shown as a neon representation. 
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4.11 Generation of new AIF-mimetics through a focused simplified peptide 
library 
In order to further optimized the peptide AIF(381-389)ox, we screened a focused 
simplified peptide library [89]. This library was designed on the basis of Ala-scanning and 
NMR results, replacing residues in positions 385-386 appearing as not directly responsible 
of the interaction with CypA. In our approach we employed a minimum number (7 instead 
of 20) of non redundant amino acids as building blocks (Figure 4.26), chosen on the basis of 
their ability to induce β-hairpin structures [114]. Positional scanning libraries were prepared 
by the solid phase method, using the “Pre-mix” [115] approach and the characterization of 
peptide mixtures was performed by pool amino acid analysis of sub-libraries, and by LC-
ESI mass spectrometry. Their experimental compositions were in agreement with a 
theoretical distribution of pseudo-equimolar mixtures (data not shown). 
The amino acids selected for the random insertion include: alanine, glycine, threonine, β-
alanine, leucine, proline and aspartic acid [114, 116]. 
The library thereby consisted of seven sub-libraries, each containing a set of seven different 
peptides, in which the position 385 was fixed and the position 386 was randomized (See 
Methods for details). 
 
  C381IKLKYX7RKV
389C 
 
 
Where Y: A, G, T, βA, L, P, D 
X7: mixture of 7 selected amino acids. 
Figure 4.26.: Schematic illustration of synthetic positional scanning libraries 
Libraries were screened in parallel on multiple plates, through Label-free Corning Epic 
technology at concentrations ranging between 0.07 µM and 150 µM (Figure 4.27). 
By data analysis, none of the screened sub-libraries showed an improved affinity toward 
CypA peptides compared to AIF(381-389)ox and this can be ascribed to a concentration 
effect. Indeed each sequence in the mixtures is 7-fold less concentrated compared to the 
wild-type AIF(381-389) single peptides. The Figure 4.27 shows the IC50 values of each 
library reported. 
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Figure 4.27: IC50 values for the sub-libraries tested. Values were calculated for each library from the dose-
response curves using a single site equation model. 
D-library
IC50=18µM ±0.5
P-library
IC50=40µM ±0.8
G-library
IC50=14µM ±0.80
βAla-library
IC50=39µM ±1.1
T-library
IC50=9.3µM ±0.7
L-library
IC50=5.2µM ±1.2
A-library
IC50=25µM ±1
 
Library Name 
 
IC50 
 
D-Library 
 
18.0±0.5 µM 
 
P-Library 
 
40.0±0.5 µM 
 
G-Library 
 
14.0±0.5 µM 
 
A-Library 
 
25.0±0.5 µM 
 
T-Library 
 
9.30±0.5 µM 
 
β-Ala-Library 
 
39.0±1.1 µM 
 
L-Library 
 
5.20±1.1 µM 
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We therefore selected the L-library, showing the lowest IC50 (5.2 ± 1.2 µM) and prepared 
the single components. Peptides were synthesized and purified by RP-HPLC and identified 
by LC-MS (data not shown). Their binding abilities to CypA were again analyzed through 
label free techniques (Figure 4.28). 
 
 
Figure 4.28: Concentration-dependent curves and IC50 values for the single peptides composing the L-library 
from the previous experiment. Values were calculated for each peptide from the dose-response curve using a 
single site equation model. 
IC50= 19.56±2.3
C381IKLKLARKV389C
Log[M]
p
m
C381IKLKLDRKV389C
IC50= 16.95±2.2
Log[M]
p
m
C381IKLKLGRKV389C
IC50= 36.0±2.8
Log[M]
p
m
IC50= 0.96±0.7
C381IKLKLLRKV389C
Log[M]
p
m
C381IKLKLTRKV389C
IC50= 18.57±3.2
Log[M]
p
m
C381IKLKLPRKV389C
IC50= 9.59±0.9
Log[M]
p
m
C381IKLKLβARKV389C
IC50= 18.2±2.2
Log[M]
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Peptide Sequence IC50 
C381IKLKLARKV389C 19.0 ±2.3 µM 
C381IKLKLTRKV389C 18.6±3.2 µM 
C381IKLKLDRKV389C 16.9±2.2 µM 
C381IKLKLPRKV389C 9.6±0.9 µM 
C381IKLKLGRKV389C 36.0 ±2.8 µM 
C381IKLKLβARKV389C 18.2±2.2 µM 
C381IKLKLLRKV389C 0.96±0.7 µM 
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These experiments allowed to select a new peptide with an affinity toward CypA largely 
enhanced compared to AIF(381-389)ox. The peptide, resulting from the introduction of two 
leucine residues in position 385 and 386, called AIF(381-389)modLL, shows the highest 
affinity to CypA, with an IC50 of 0.96  ± 0.7µM. 
 
4.12 Characterization of a new peptide: AIF(381-389)modLL peptide 
Structural studies on AIF(381-389)modLL, performed by CD, have shown that the presence 
of the two leucine, results in a significant increase of well organized structures compared to 
the parent AIF(381-389)ox peptide.  
As shown in Figure 4.29, AIF(381-389)modLL has a positive maximum at 195 nm and a shift 
of the absolute minimum from 198 nm to 202 nm, indicative of a very well defined 
conformation. 
The data suggested that the selected peptide represents the best template for the design and 
selection of new specific antagonists of the complex AIF/CypA. 
 
Figure 4.29: CD spectra of AIF(381-389)modLLand of AIF(381-389)ox. 
 
Biological studies are underway to evaluate the effects of the new peptide on apoptosis 
mechanisms. Ligand-based structural studies are also in progress to design new molecules or 
peptidomimetic for further structural and functional improvements and for potential 
application in in vivo models of AIF-dependent neurological diseases. 
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5. DISCUSSION 
Protein-protein interactions (PPIs) are known to play a critical role in the normal 
function of cellular structure, immune response, protein enzyme inhibitors, signal 
transduction, and apoptosis [117]. 
The ability of proteins to assemble into different protein complexes in cellular environments 
enables these macromolecules to perform different functional roles. 
The molecular recognition between proteins and the identification of compounds that might 
inhibit such interactions and control chemical complex formation is a major challenge in the 
drug discovery field. 
Several studies have demonstrated that PPIs can be addressed with small molecule drugs, 
however the large surfaces and the several contact points involved make this task difficult 
[118]. 
In the last years, research efforts have focused on inhibitors able to interact with the protein 
targets on multiple hot-spots thanks to their large size and intrinsic flexibility. 
Peptides can fulfil this task and have the further advantage of simple preparation by 
the solid phase method and straight forward structural characterization by NMR [119]. For 
these reasons, peptides have drawn the attention for innovative drug development. 
The availability of structural information on protein-protein complexes and the possibility to 
readily map protein segments that participate in protein-protein interactions [120] allowed 
the rational design of new bioactive peptides, that are becoming increasingly attractive as 
potential drug candidates. 
A useful method to search for peptides that inhibit a protein-protein interaction is to mimic 
the segment of one of the interacting proteins with the corresponding synthetic peptides. 
This general approach constitutes the essential cornerstone of this work that is focused on 
the identification of specific inhibitors of the AIF/CypA complex, whose formation is 
involved in relevant apoptotic processes. 
Apoptosis-inducing factor (AIF) is a highly conserved, phylogenetically old 
mitochondrial flavoprotein implicated in embryonic development, cardiac cell survival, 
carcinogenesis and neurodegenerative disorders [34]. 
Several studies in vitro and in vivo have demonstrated that the pro-apoptotic action of AIF 
in neurological disorders is triggered by its release through mitochondrial membrane and its 
translocation to the nucleus, where induces chromatinolysis [30].  
The translocation of AIF to the nucleus after cerebral hypoxia-ischemia, requires interaction 
with Cyclophilin A (CypA), suggesting a model in which the two proteins, that normally 
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reside in separate cytoplasmic compartments, acquire novel properties when moving 
together to the nucleus [54]. 
A model of docking between CypA and AIF suggested that CypA and AIF establish 
extensive molecular contacts [72]. 
Recent data demonstrated that the region 370-394 of AIF, predicted from this model, is 
involved in the interaction with CypA [71]. 
Indeed the peptide mimicking this region, AIF(370-394), bound CypA with an 
affinity in the low micromolar range (KD= 4.7 ± 0.2 µM) and provided neuroprotective 
effects in HT-22 cells, a model of AIF-mediated neuronal cell death, by inhibiting the 
formation of the AIF-CypA lethal complex. 
A major disadvantage of using this peptide in cellular experiments and in perspective in 
vivo, is associated with the difficulty to transduce it into cells and in neuronal tissues. 
On this basis, the aim of this work was focused on the identification of new peptide 
inhibitors of the AIF/CypA complex designed on the peptide AIF(370-394) and possessing 
an improved pharmacokinetic profile. 
To this end, we designed, synthesized and characterized by NMR and biochemical assays, a 
series of new peptides to reduce the size of the parent molecule and to identify the crucial 
hot spot residues involved in the interaction. These data will be useful for the design of 
peptidomimetics or molecules with a therapeutic potential. 
In order to identify the AIF(370-394) residues more involved in the recognition with 
CypA, we performed Saturation Transfer Difference (STD) NMR experiments using the 
recombinant CypA protein in complex with the synthetic AIF(370-394) peptide. 
1H-STD NMR experiments demonstrated that several aminoacids arranged along the 
sequence of the peptide are involved in the interaction with CypA and that most of them are 
included in the region 380-390.  
On the basis of these data, a new AIF peptide, spanning residues from 380 to 390, named 
AIF(380-390), was synthesized and characterized.  
Remarkably, this region adopts a -harpin conformation in the full length protein, as 
demonstrated by the crystallographic structure of AIF protein [32], we therefore introduced 
two cysteine residues at N and C terminus to promote the -hairpin conformation by a 
disulfide-bridge.  
The decrease of the molecular surface caused the expected reduction of affinity toward the 
target protein. Indeed, AIF(380-390)red showed a KD value of 30 ± 2µM, about 6-fold 
higher than that of the parent AIF(370-394) (KD= 4.7 ± 0.2 µM).  
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Notably, the cyclization of the peptide through the two cysteines restored the affinity to 
CypA (KD= 3.2 ± 0.2 µM), indicating a direct correlation between the structure and activity 
of the peptide. 
We next evaluated the role of each amino acid of the new cyclic peptide in the 
interaction with CypA, by an Ala scanning approach. Each single amino acid was 
systematically substituted with an alanine and the resulting peptides were tested in direct 
binding assay with CypA. 
Data showed that the critical residues of AIF(380-390)ox peptide for the CypA recognition 
were K382, K384,K387 and R388, while residues L380, E390, D385 and G386 appeared poorly 
involved in the interaction with the target protein, in agreement with the STD-NMR data on 
AIF(370-394) in complex with CypA. 
A preliminary NMR analysis of the cyclic AIF(380-390) peptide also showed the presence 
of different conformations, stabilized by salt bridges between the carboxyl group of E390 
and theε-amino group of the various lysine salong the sequence. 
We thus designed and synthesized a smaller cyclic peptide encompassing the region 
381-389, called AIF(381-389)ox.  
Interestingly, this last peptide bound CypA with an affinity similar to that of AIF(380-
390)ox, in agreement with the Ala-scanning and NMR data.  
This peptide also resulted more structurally homogeneous around a -hairpin conformation, 
as indicated by NMR studies. 
Although the affinity of the new peptide was comparable to that of AIF(370-394), a 
significant difference was observed in cell-based assay. Indeed, both AIF (381-389)ox and 
AIF (380-390)ox provided a greater neuroprotection against glutamate treatment in HT-22 
cells, compared to the precursor peptide. 
NMR binding studies of AIF(381-389)ox with the protein were performed by both chemical 
shift perturbation (CSP) analysis, using 15N-labelled CypA, and by STD experiments, using 
the peptide and the unlabelled protein. These NMR data were used to generate a docking 
model of the CypA-AIF(381-389)ox complex. 
Data clearly showed that CypA residues mostly involved in the interaction with 
AIF(381-389)ox are located on a contiguous region very close to the catalytic site of CypA. 
Moreover, the interacting residues on AIF(381-389)ox were included in the recognition 
region of AIF(370-394)/CypA, as also shown by other studies (unpublished data). 
Although structure-based design represents an important approach for the development of 
inhibitors of protein-protein interactions, another useful approach is based on the screening 
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of combinatorial collections. In this case, starting structural information on protein and 
peptide interacting regions, our purpose was the further enhancement of native conformation 
of the peptide, to obtain a more active compound. 
To this end, starting from STD and Ala-scanning results, we prepared and screened a 
simplified short combinatorial library, obtained replacing the amino acids D385 and G386, 
poorly involved in the interaction with CypA, with residues known as inducer of turns, such 
as alanine, glycine, threonine, -alanine, leucine, proline and aspartic acid. 
We designed and synthesized seven peptide pools, each containing a set of seven 
different peptides, in which the position 385 was fixed and the position 386 was randomized 
with a mixture of preselected amino acids. 
Testing these libraries by direct-binding assays, demonstrated that all had KD values in the 
micromolar range. The L-library, however, where in position 385 a leucine was present, 
displayed a stronger binding. 
The seven single peptides composing the L-library, were synthesized and tested, 
selecting a new peptide, where both position 385 and 386 were occupied by a leucine. 
This peptide (C381IKLKLLRKV389C), named AIF(381-389)modLL, showed an affinity for 
CypA in the nanomolar range. 
Structural studies performed on this peptide showed a higher content of secondary structures 
compared to AIF(381-389)ox, proving the contribution of leucine residue to the overall 
peptide stability. 
In conclusion, by this work we have identified the minimal region of AIF involved in 
the interaction with CypA. This region corresponds to the cyclic nonapeptide AIF(381-
389)ox, obtained by a systematic and structure-driven approach of size reduction of the 
original AIF(370-394) template, containing 25 residues. 
A docking model of the CypA/AIF(381-389)ox complex has also been generated 
which will be used for structure-based drug design of new compounds inhibiting the 
AIF/CypAcomplex. 
The amino acid sequence of this AIF peptide has been further optimized to obtain 
AIF(381-389)modLL by changing two key residues that induce the β-hairpin conformation 
adopted by this fragment in the native AIF protein. 
Cellular experiments in HT-22 neurons with AIF(381-389)modLL are currently ongoing to 
assess its therapeutic potential. 
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ABSTRACT 
In this work, a sensitive and convenient protease-based fluorimetric HTS assay for 
determining prolyl-peptidyl cis-trans isomerase activity was developed. 
The assay was based on a new intramolecularly quenched substrate, whose fluorescence and 
structural properties were examined together with kinetic constants and the effects of 
solvents on its isomerization process.  
Pilot screens performed using the LOPAC library and Cyclophilin A, as isomerase model 
enzyme, indicated that the assay is robust for HTS, and that comparable results are obtained 
with CypA inhibitor tested both manually and automatically.  
Moreover, a new compound that inhibits CypA activity with an IC50 in the low micromolar 
range has been identified.  
Molecular docking studies revealed that the molecule shows a notable shape 
complementarity with the catalytic pocket confirming the experimental observations. 
Due to its simplicity and precision in the determination of extent of inhibition and reaction 
rates required for kinetic analysis, this assay offers many advantages over other commonly 
used assays. 
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7. INTRODUCTION 
7.1 Peptidyl-prolyl isomerases (PPIases) family  
Peptidyl-prolyl cis-trans isomerases (PPIases) are ubiquitously expressed and highly 
conserved proteins found both in prokaryotic and in eukaryotic cells [1-5]. 
PPIases, on the basis of drug specificity and primary sequence homology, have been divided 
into three distinct families: i) the cyclosporin A (CsA)-binding proteins, cyclophilins, ii) the 
FK506 and rapamycin binding proteins, FKBPs, and iii) the parvulins, which do not bind 
immunosuppressant drugs [1-5]. 
The principal function of PPIases is to participate in protein folding by catalyzing the cis-
trans isomerization of X-Pro peptide bonds in polypeptide chains (where X is any amino 
acid) [1-5]. Among all aminoacids, the proline is unique able to adopt completely distinct cis 
and trans conformations, which allow it to act as a backbone switch controlled by prolyl cis-
trans isomerization (Figure 7.1). 
 
 
The Figure 7.1 shows the trans and cis isomers of the peptide bond between proline (on the 
left of each structure shown) and another amino acid (P1, on the right).  
The interconversion between the two forms is catalyzed by cyclophilins and other peptidyl-
prolyl isomerases (PPIases). The carbon atoms of the proline are indicated by Greek letters; 
P2 indicates a third amino acid on the other side of the proline. The peptide bond has some 
double-bond character and is planar. 
The local environment of the proline can influence the relative free energies of the 
cis and trans isomeric states leading to wide variations in the ratio of cis/trans populations 
in different proteins and peptides. In the context of native protein folds, most structures 
require proline to adopt one or the other isomer.  
Figure 7.1: Schematic illustration of the reaction catalyzed by the cyclophilins
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When ΔG is small, both isomers are significantly populated at thermal equilibrium. 
However, due to the relatively large energy barrier (ɛu=14–24 kcal/mol), uncatalyzed 
isomerization is a rather slow process with an exchange time constant (Ʈex) on the order of 
several minutes (Figure 7.2).  
PPIases can reduce the energy barrier between cis and trans states (ɛcat,) and dramatically 
accelerate isomerization, reducing Ʈex to the millisecond regime, a more meaningful 
timescale for regulation of the timing of biological processes [6]. 
 
 
The conformational interconversion of the backbones of signaling proteins mediated 
by peptidyl prolyl cis-trans isomerization plays a pivotal role in many aspects of cellular 
processes, including post-translational modifications like phosphorylation and glycosylation, 
whose dysregulation does contribute to the development of many human diseases (Figure 
7.3) [4, 7-10]. 
 
For this reason, great efforts are spent on the identification of specific PPIase modulators for 
Figure 7.2: Conformational exchange in high-energy t ransition state.
Conformational exchange proceeds through the twisted 90-syn high-
energy transition state in the intrinsic (blue curve) or PPIase-catalyzed
(red curve) reactions.
Figure 7.3: Involvement of PPIases function in development
of many cellular processes
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therapeutic approaches. However, the discovery of novel inhibitors has been limited by the 
lack of suitable assays for high-throughput screenings (HTS). 
In this study, particular attention is given on the role of Cyclophilin A and its activities as 
PPIase protein. 
 
7.2 Studies on CypA PPIase activity 
CypA is the most important member of the family of human Cyclophilins [11-13]. 
CypA plays a critical role in a variety of biological processes including protein folding, 
trafficking, assembly, immunomodulation and cell signaling [14-16]. 
Moreover, besides its physiological role, the PPIase activity of CypA is also implicated in 
various pathological conditions and diseases, including viral infection, cancer and 
neurodegeneration [17]. 
Conventionally, the enzymatic activity of PPIases has been determined by UV/Vis 
spectrophotometry with N-succinylated tetrapeptide-4-nitroanilides (pNA) as standard 
substrates (Succinyl-Ala-Xaa-Pro-Phe-pNA) [18]. 
This assay is based on the conformational specificity of chymotrypsin, which cleaves the 
pNA moiety from the substrate only when the Xaa-Pro amide bond is in the trans 
conformation.  
In the presence of PPIases, the Xaa-Pro bond is more rapidly converted to the trans 
conformation, and the substrate is then more readily cleaved by chymotrypsin leading to the 
formation of the colored product pNA [18].  
This method, however, suffers from low sensitivity of the chromogenic compound, as well 
as the fast spontaneous cis-trans isomerization which translates in the rapid processing of 
the substrate (generally in the range of seconds) by Chymotrypsin [18]. 
Since the spontaneous cis-trans isomerization is too fast for reliable calculation of rate 
constants at room temperature, the assay is usually carried out at or below 10 °C. 
However, even under these conditions, a typical half time of the uncatalyzed cis-trans 
isomerization is about 100 s.  
In the attempt to develop new more and sensitive assays suitable for HTS programs, 
several fluorescent new probes and detection methods have been developed for highly 
sensitive detection of PPIase activity [19-21]. 
However, to date, no fluorogenic substrates for monitoring PPIase activity in HTS modality 
have been reported. 
The main features of HTS-compatible assays include robustness, sensitivity, automation and 
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miniaturization. Sensitivity, in this instance, is intended as the capability to generate signals 
sufficiently higher than the noise but also the ability to detect small inhibition differences.  
Robustness instead refers to the possibility to have an assay readout stable and reproducible 
in a time range adequate to the assay timelines [22]. 
In this framework, we have designed and tested a novel peptide substrate targeting the 
catalytic site of CypA and useful in HTS-based protease-coupled PPIase assays.  
To transfer the assay in a HTS format, we have investigated and optimized parameters like, 
buffer composition, reaction time, enzyme/substrate ratio, and DMSO content. The 
conditions for achieving optimal signal-to-noise (S/N) and Z′-factor values have been 
identified. 
Moreover, using the optimized and automated assay, we selected a small molecule inhibitor 
(< 500 Da) of CypA by the screening of the LOPAC library. 
The inhibitor shows an IC50 in the low micromolar range, and molecular docking studies 
suggest how it interacts and occupies the catalytic groove of CypA. 
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8. AIMS OF THE PROJECT 
In this study, we developed a sensitive and robust HTS method for monitoring the 
peptidyl prolyl cis-trans isomerase activity of human Cyclophilin (CypA). 
CypA catalyses the slow, rate-limiting cis-trans isomerisation of peptidyl-prolyl bonds. 
Great efforts are paid for the development of robust and sensitive assays, useful for selecting 
specific PPiase modulators for therapeutic approaches. 
The catalytic activity of PPIases is normally monitored spectrometrically by using the 
chymotrypsin-coupled assay. 
The discovered HTS method was used to identify prototypical inhibitors from LOPAC, a 
commercial library of bioactive drugs.  
In order to assess its usefulness in High Throughput Screenings, we have optimized the 
method on 384-well plates and automated the screening process on a HTS platform. 
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9. MATERIAL AND METHODS 
9.1 Substrates and chemicals 
Protected amino acids, Coupling agents (HATU) and Fmoc-Rink Amide AM Resin used for 
peptide synthesis werepurchased from IRIS Biotech GmbH (Marktrewitz, DE). Fmoc-
Glu(EDANS)-OH and Fmoc-Lys(Dabcyl)-OH were from PolyPeptide Group (Strabourg, 
France). Solvents, including acetonitrile (CH3CN), dimethylformamide (DMF), 
trifluoroaceticacid (TFA) and methanol (CH3OH) were purchased from ROMIL (Dublin, 
Ireland). Other products such as Sym-collidine, DIPEA, Piperidine, CyclosporinA (CsA), α-
Chymotrypsin (hereafter only Chymotrypsin) from bovine pancreas (TLCK-treated to 
inactivate residual trypsin activity) and LOPAC1280 small library were from Sigma-Aldrich 
(Milan, Italy). Analytical HPLC analyses for monitoring the cis-trans transition were 
performed on an AllianceHT WATERS 2795 system, equipped with a PDA WATERS 
detector 2996. Preparative purifications were carried out on a WATERS 2545 preparative 
system (Waters, Milan, Italy) fitted out with a WATERS 2489 UV/Visible detector. LC-MS 
analyses were performed using a ESI Ion Trap HCT ETD IIHCUltraPTM discovery system 
Bruker mass spectrometer coupled with an HPLC System Alliance e2695 separation module 
fitted out with a 2998 PDA detector (Waters, Milan, Italy). A automated MICROLAB 
STAR Liquid Handling Workstation from Hamilton Robotics (Bonaduz, Switzerland) was 
used to develop the screening assay. The work-station includes a set of eight independent 
pipetting channels, several positions for sample tubes and plates, the barcode identification 
for samples, microplates, reagents and carriers. The liquid handler was implemented with 
the Total Aspiration and Dispense Monitoring (TADM) system, with the Liquid Level 
Detection system and the Tip Attachment (CO-RE) system. In all procedures, the Monitored 
Air Displacement (MAD) system was used. All workstation functions and integrated third-
party devices were controlled by the Venus software (Hamilton Robotics, Bonaduz, 
Switzerland). AnEnSpire Multimode Plate Reader (Perkin Elmer) was used to perform 
fluorescence measurements. 
 
9.2 CypA expression and purification 
Recombinant His6tagged-CypA was efficiently expressed in BL21(DE3) E. Coli 
cells and purified and characterized, as previously reported in Materials and Methods 
section 3.2.1. Protein concentration was determined by reading the absorbance at 280 nm in 
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combination with the theoretical molar extinction coefficient (8730 M−1cm−1) using the 
NanoDrop200c UV-Vis spectrophotometer (Thermo Scientific). The His6 tag was not 
removed from the protein. 
 
9.3 Peptide synthesis 
Peptides were synthesized on solid phase using Fmoc-protected L-amino acids [23] and 
RINK AMIDE Resin AM with 0.71 mmol/g loading supplied by IRIS Biotech GmbH. 
In particular, the deprotection of Fmoc from the α-amino groups was achieved by a 
preliminary treatment with 40% piperidine in DMF for 5 min followed by a second 
treatment with 20% piperidine in DMF for 15 min.  
Couplings with amino acids were carried out by pre-activation with 4 equivalent of HATU 
(2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl-uronium-hexafluorphosphate), [24] 4 
equivalents of Fmoc-protected amino acids and 8 equivalents of Sym-Collidine (relative to 
the synthesis scale), for 5 min and adding the mixture to the resin for a reaction time of 45 
min under continuous mixing. For HPLC analysis peptides were cleaved from the resin 
leaving the Fmoc group at N-terminus. 
The peptide having the Dabcyl/EDANS FRET pair at the C- and N-terminus (FRET 
substrate) used in the HTS assay, was generally synthetized as previously reported. 
However, the introduction of the N-terminal Fmoc-Lys(Dabcyl) and of the C-terminal 
Fmoc-L-Glu(EDANS)-OH was achieved by a double coupling using 2eq at each coupling 
round, [25] and a longer reaction time (3 h). 
Cleavage of the final peptide from the resin was accomplished by treatment with TFA-TIS-
H2O mixture (90:5:5, v/v/v) and subsequent precipitation in cold diethyl ether. 
Lyophilized peptides were purified using an Onyx monolithic semi-PREP C18 column 
(100x10mm, Phenomenex, Castel Maggiore, Italy) operated at a flow rate of 15 mL/min; 
H2O+0.1% TFA and CH3CN+0.1% TFA were used as eluents, using a linear gradient from 
10% to 60% of CH3CN+0.1% TFA in 20 minutes.  
Peptides were characterized by LC-MS, determining purity and MW of final compounds. 
 
9.4 HPLC analysis 
Time- and concentration-dependent isomerase activity of CypA were evaluated by HPLC 
using the new Fmoc substrates. The conditions used were as follows: Onyx monolithic C18 
column (50x2 mm) operated at a flow rate of 0.6 mL/min; eluents: H2O+0.1% TFA and 
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CH3CN+0.1% TFA; wavelength 265.8 nm. A linear gradient from 15% to 80% of 
CH3CN+0.1% TFA in 4 minutes was applied to elute the products. 
The differences between CypA-catalyzed and spontaneous cis-trans isomerization rates of 
the Fmoc-protected substrates were evaluated by following the Fmoc-full length peptide 
signal reduction and/or the increase of chymotrypsin-hydrolyzed Fmoc-peptide at 265.8 nm 
(maximum Fmoc absorption). 
The assays were carried out at room temperature and in a volume of 200 μL, by using the 
substrates at 10 ng/μL, commercial Chymotrypsin at 100 ng/μL and CypA at 200 ng/μL. 
Assays were performed in two different buffers, HEPES 35 mM and LiCl 5 mM or HEPES 
35 mM and NaCl 150 mM to evaluate the effect of positive ions on the population of cis 
conformers and on the reaction kinetics. 
Signal-to-background ratio (S/B) was defined as the XP/XN ratio of peak areas obtained for 
the PPcut and EPPcut peptides during the CypA-assisted (XP) and not assisted (XN) 
Chymotrypsin cleavage. 
 
9.5 Assay automatization 
The chymotrypsin-coupled enzymatic assay was performed in 384-well black solid bottom 
plates (PerkinElmer) in a total volume of 50 μL in each well using the new FRET substrate. 
For assays on full 384-well plates, Chymotrypsin, CypA and FRET substrate solutions in 
Reaction Buffer (PBS 1X, pH 7.4) were prepared at a concentration 4-fold higher than that 
of the final concentration used in the assay. Solutions of inhibitors were prepared in 96 well 
plates (mother plates) at 4X concentration in the Reaction Buffer. 
The procedure consisted of the following steps: 
(1) Dilution of compounds from the stock solution (in DMSO) in the reaction buffer in the 
mother plate. 
(2) Dispensing 12.5 μL of buffer or inhibitor solution into 384-wells of black OptiPlate-384. 
(3) Addition of 12.5μL of FRET substrate at concentration of 60 ng/μL. 
(4) Addition of 12.5 μL of CypA at concentration of 2.2μg/μL. 
(5) 30 min incubation at room temperature, in the dark. 
(6) Addition of 12.5 μL of Chymotrypsinsolution at 600 ng/μL. 
(7) Reading over time fluorescence, (λex =340 nm and λem=510 nm). 
Experiments were run as quadruplicate and reported as averaged values ± standard deviation 
(±SD). 
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9.6 Assay Parameter Calculations 
The signal-to-noise ratio (S/N) was calculated by using the equation 
S/N =
                                                       
                                          
.The Z'-factor values in all 
conditions tested were calculated as reported in literature [26]. 
In the assays, Chymotrypsin at final concentration of 150 ng/μL was added in 384-well 
plates in which the substrate and CypA were already dispensed following the protocol 
reported before, and fluorescence was recorded after 30 min. 
The assay was performed also in the presence of increasing amounts of DMSO to simulate 
the experimental conditions where by compounds from stock solutions in this solvent are 
submitted to screening. The chosen concentrations of DMSO were 1, 2, and 3% to simulate 
dilutions of 10 mM stock solutions in neat DMSO up to 100, 200, and 300 μM. Most 
compounds were soluble in this solvent at the indicated concentrations. 
The Z'-Factor was determined at 0, 1, 2, and 3% DMSO concentrations on 32 independent 
data points for each condition. 
 
9.7 IC50 Determination 
Dose-dependent assays with the known inhibitor CsA and with the hit inhibitors were 
performed at concentrations ranging between 0.001 and 25 μM for the CsA and between 
0.001 and 50 μM for the selected inhibitors. 
The FRET substrate, the CypA and the hits were incubated for 30 min at room temperature. 
After the incubation Chymotrypsin was added and after 30 min fluorescence was detected. 
For all these assays, each data point was in quadruplicate. 
Experimental data were fitted with GraphPad Prism, vers. 5.00, GraphPad Software (San 
Diego, California). 
 
9.8 Determination of the Steady-State kinetic parameters for EPP 
substrate 
To determine the Km/Kcat values the FRET substrate was serially diluted in PBS 1X pH 7.4 
(from 1 to 250 μM). The peptide was then mixed with CypA at final concentration of 600 
ng/μL and Chymotrypsin at 150 ng/μL.  
After 30 min the fluorescence of EDANS was measured at 510 nm upon excitation at 340 
nm. 
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9.9 NMR spectroscopy 
All NMR experiments were carried out at 298.0 K using an Inova 600 MHz spectrometer 
(Varian Inc., Palo Alto, CA, USA), equipped with a cryogenic probe optimized for 1H 
detection.  
NMR data were collected on samples of EPP substrate without the Fmoc group to improve 
solubility. We assumed that the presence/absence of this group did not alter the cis-trans 
equilibrium. 
Samples were prepared by dissolving the peptide at concentration of 600 M in 20 mM 
sodium phosphate buffer pH 7.0 containing 10% 2H2O (500 μL) in presence of 150 mM 
NaCl or 5 mM LiCl.  
For the one-dimensional (1D) 1H spectra, 64 scans were acquired with a spectral width of 
6714.8 Hz, relaxation delay 1.5 s, 16.384 data points for acquisition and 32,768 for 
transformation.  
The two-dimensional (2D) [1H, 1H] DQF-COSY [27], TOCSY [28], NOESY [29] and 
ROESY [30] spectra were acquired using the TPPI method to obtain complex data points in 
the t1 dimension. 
Typically, 32 or 64 scans per t1 increment were collected with a spectral width of 6714.8 Hz 
along both f1 and f2, 2048 × 256 data points in t2 and t1, respectively, and recycle delay 1.5 s. 
Water suppression was achieved by means of Double Pulsed Field Gradient Spin Echo 
(DPFGSE) sequence [31, 32]. 
The TOCSY experiment was recorded using a DIPSI-2 mixing scheme of 70 ms with 7.7 
KHz spin-lock field strength. The NOESY spectra were carried out with a mixing time in 
the range of 250-450 ms.  
The mixing time of the ROESY experiment was 200 ms. The data were typically apodized 
with a square cosine window function and zero filled to a matrix of size 4096 × 1024 prior 
to Fourier transformation and baseline correction.  
Chemical shifts were referenced to internal water at 4.75ppm.  
All NMR data were processed with the software VNMRJ 1.1.D (Varian Inc.). 1D spectra 
were analyzed using ACD/NMR Processor 12.0 (www.acdlabs.com). 2D spectra were 
analyzed using CARA (Computer Aided Resonance Assignment) software [33]. 
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9.10 Fluorescence spectroscopy 
Fluorescence measurements were performed on an EnSpire Multimode Plate Reader, Perkin 
Elmer and the assay was adapted to 384 well black plates in a total volume of 50 μL. 
The intrinsic tryptophan fluorescence of CypA was determined by excitation at 295 nm and 
reading the emission at 340 nm.  
The equilibrium dissociation constant KD for the CypA-C3353 interaction was determined 
by fluorescence titration at 15 μM protein concentration in PBS 1X at pH 7.4. 
Aliquots of the non-fluorescent molecule in 1% DMSO were added to the protein solution 
and the resulting fluorescence intensities were measured. 
The final and constant DMSO concentration was 1%. A plot of the corrected fluorescence 
intensity versus ligand concentration was fitted with a one-site binding model  
The reported KD values were averages from three independent titrations. 
 
9.11 Molecular Modeling 
The coordinates for compounds D138 and C3353 were downloaded from MMsINC database 
[34], already energy minimized and with the partial charged assigned (MMs03080181 and 
MMs00455114, respectively).  
To identify the more appropriate protocol for molecular docking studies, a self-docking 
benchmark using DockBench 1.01 software [35] was performed.  
This procedure compared the performance of 17 different posing/scoring protocols to 
reproduce experimental derived complex geometries.  
In the benchmark study, four crystal structure available in the protein data bank [36] were 
submitted to calculations, PDB ID: 3RDD, 4N1N, 4N1Q and 4N1R [37, 38, 39, 40]. 
Water molecules present in the pdb file were removed and the complexes were subjected to 
the structure preparation tool of MOE 2015 [41]. 
Finally the function Protonate3D [42] included in MOE 2015 [41] was used to assign the 
protomeric state at pH 7.4. The active site was defined using a radius of 12 Å from the 
centre of mass of the co-crystallized ligand. Each ligand was docked 20 times. 
The ligands identified in the HTS were finally docked using the virtual screening tool of 
DockBench 1.01 on the protein conformation 3RDD, using GOLD [43] and Goldscore [44] 
as posing algorithm and scoring function respectively, with the same parameters adopted in 
the benchmark stage. The molecular docking analysis were performed with MOE 2015 [41]. 
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10.  RESULTS 
10.1 Design and testing of substrates 
Two new PPIase substrates, here after named PP and EPP, were designed in order to 
force their structures, at room temperature and in absence of organic solvents, in a 
predominantly cis conformation and thus to enhance assay sensitivity.  
Specifically, besides the consensus sequence Pro-Phe (P-F) present in common PPIase 
substrates, a second P was inserted before the P-F segment, [46] as suggested by several 
other studies [47]. 
Moreover, a lysine (K6 in PP peptide or K8 in EPP peptide) was introduced in both 
sequences to improve the peptide solubility. A glutamic acid was inserted at the N-terminus 
of the EPP peptide (E1) to potentially stabilize the cis conformation of the X-Pro bond 
through a salt bridge with the K8 at the C-terminus [48, 49]. 
Both peptides bore an Fmoc group on the N-terminus to facilitate identification and 
detection by HPLC. The sequences of PP and of EPP are reported in Figure 10.1 together 
with the fragments resulting from Chymotrypsin cleavage.  
 
Peptide Sequence MWcalc MWexp ([M+H)
+]) Rt(min)
a 
PP Fmoc-APPFAKA-NH2 921.33 922.2 3.20 
PPcut Fmoc-APPF-OH 652.60 653.0 3.60 
EPP Fmoc-EAPPFAAKA-NH2 1121.55 1122.4 3.01 
EPPcut Fmoc-EAPPF-OH 781.60 782.1 3.35 
 
Figure 10.1: Sequences of peptides used for monitoring the CypA isomerase activity through HPLC. 
Analytical data are reported for both the precursors and the reaction products with Chymotrypsin. 
Peptides were easily synthesized using the standard solid-phase-Fmoc method [23]. Yields 
were on average greater than 60%. 
CypA used in the assays was overexpressed in BL21(DE3) E.Coli cells with a tag of 
6 histidine and purified to homogeneity by a single step of affinity chromatography. Typical 
yields were 20 mg/L. Time- and concentration-dependent isomerase activity of CypA were 
evaluated by HPLC using the PP and EPP substrates conjugated with the Fmoc group. 
In Figure 10.2 A-D representative HPLC chromatograms of reaction products after 40 
minutes incubation time are reported. Substrates were characterized by a single peak with a 
retention time of 3.20 min and 3.10 min, for PP and EPP respectively (Figure 10.2).  
  
Figure 10.2: Chymotrypsin coupled isomer
chromatograms of spontaneous (solid lines) and CypA
lines), after 40 min incubation at room temperature.
LiCl 5mM, pH 7.4 is shown; in 
C the experiment with the EPP substrate in Hepes
with EPP in Hepes 5 mM, NaCl 150mM, pH 7.4 is shown. The measurement were carried out in the 
absorbance mode at 265.8 nm. 
After treatment with Chymotrypsin
peaks with retention times 
cleaved EPP (EPPcut) were detected (
experimental masses of the processed and unprocessed substrates are summarized in
10.1. Results obtained with the PP and EPP 
substantial population of cis
the presence of large amounts of Chymotrypsin unprocessed peptides in the absenc
CypA (see peaks at 3.10 and 3.20 minutes, solid lines 
However, comparative data indicated that Chymotrypsin processing was strongly reduced 
-specific proteolysis HPLC assay.(A-C
-catalyzed cis-trans isomerization
 In A the experiment with the PP substrate in
B the experiment with PP in Hepes 5mM, NaCl 150 mM, pH 7.4 is shown; in 
 5mM, LiCl 5mM, pH 7.4 is shown; in 
 alone and/or the Chymotrypsin/CypA mixture
of 3.60 min for the cleaved PP (PPcut) and 3.35
Figure 10.2 A-D). Retention times, theoretical and 
indicated that in our experimental conditions,
-conformers was present in both substrates as demonstrated by 
in Figure 10.2 A-D).
98 
 
) Representative HPLC 
 process (dashed 
 Hepes 5mM, 
D, the experiment 
, new 
 min for the 
 Figure 
 a 
e of 
 
 with the EPP substrate in the presence of NaCl 
substrate, Na+ ions stabilized more efficiently the 
The higher population of cis
higher efficiency of CypA to convert them into 
Chymotrypsin cleavage (Figure
subsequent investigations. 
  
10.2 DMSO tolerance, and assessment of CypA inhibitor
Most bioactive compo
solvents, there by compounds used in high throughput screening (HTS) are typically 
dissolved in DMSO starting stock solutions
developed in presence of this
We therefore carried out time course ex
(200ng/μL) and Chymotrypsin (100ng/μL) in Hepes 5 mM, NaCl 150 mM, pH 7.4 at 
increasing concentrations of DMSO (from 0.5% to 5%) and measuring the enz
as described above. Assay performances in t
signal-to-background ratios (S/B)
A detrimental effect of DMSO 
10.3 A). 
Figure 10.3: DMSO tolerance test
was evaluated calculating the signal
5%).Values were calculated as X
under the selected conditions. Normalized peak area of HPLC chromatograms
substrate (EPP) with and without 10 μM
incubation time. Responses were
catalysed reaction in samples with and without CsA. 
(Figure 10.2 D), suggesting th
cis conformers compared to Li
-conformers in EPP in the presence of NaCl translated into a the 
trans-conformers, thus
 10.2 D). EPP in NaCl-containing buffer was chosen for 
 
unds are characterized by very low solubility in aqueo
. For this reason enzymatic assays are mostly 
 organic solvent.  
periments using the EPP substrate (10 ng/μL), CypA
hese conditions were evaluated in terms of 
 calculated as described in the section of Methods.
was observed for concentrations greater 
 and evaluation of the known CypA inhibitor CsA. (
-to-background (S/B) at different concentrations of DMSO (from 1% to 
P/XN, as described in the Methods. (B) Evaluation of
 of chymotrypsin 
 CsA, in Hepes 5 mM, NaCl 150 mM, pH 7.4, at zero and 40 min of 
 calculated as ratio between EPP peak area of spontaneous and
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at, for this 
+ ions [50]. 
 prone to 
us 
 
yme kinetic 
 
than 3% (Figure 
 
A) The DMSO tolerance 
 CsA inhibitory effect 
– processed 
 CypA-
 However, the value obtained in 
to enable optimal performances in the 
We also evaluated the effect 
conditions [2, 3]. 
Reactions were conducted 
low solubility of CsA. In Figure
calculated by subtracting the signal of spontaneous 
reaction in samples with and without CsA. 
Results obtained demonstrated that the presence of CsA interfered with
activity reaching the total inhibition at 2
 
10.3 NMR structural characterization of the new CypA substrate
To provide more useful 
we performed NMR analysis on th
different ions. In particular, 1D 
of the peptide were acquired in phosphate buffer in 
According to the presence of two X
conformational states (numbered from 1 to 4) 
equilibrium. Indeed, as can be seen in 
P3-P4 segment exhibited four
and LiCl). 
Figure 10.4: NMR structural characterization of the EPP substrate.
region of the 2D [1H, 1H] TOCSY spectra of the peptide in PBS 1X (
LiCl (B). Four correlation HN-Hβ
conformers. 
 
However, different relative peak intensities, correlating with the relative populations of the 
four conformers, were observed in the two buffer tested. The F5
the presence of 3% DMSO (~1.5) was still sufficiently high 
assays. 
of the natural inhibitor CsA on CypA isomerase activity
as described above in the presence of 1% DMSO, because of the 
 10.3 B is reported the resulting HPLC chromatogram
reaction from that of the CypA
 
 
-fold molar excess over CypA (Fig
insights into the conformation of the selected EPP 
e Fmoc-free peptide in aqueous buffer
1H and 2D [1H, 1H] TOCSY, NOESY and ROESY spectra 
the presence of either 
-Pro peptide bonds (A2-
were expected in a slow
Figure 10.4, the F5 HN, immediately following the 
 different chemical shifts in either saline buffer tested (
 Expansion of the H
A) and phosphate buffer containing 5
 F5 cross-peaks are observed, one for each of the four (1
 HN-Hβ
100 
 in our 
 
-catalysed 
the CypA isomerase 
ure 10.3 B). 
 
substrate 
s containing the 
LiCl or NaCl. 
P3 and P3-P4) four 
-exchange 
NaCl 
 
N-aliphatic correlation 
 mM 
-4) expected cis-trans 
 cross-peak volumes 
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from TOCSY spectra were used to determine the relative conformer populations which are 
listed in Figure 10.5. 
Conformers 
 
AlaPro and ProPro 
Conformationsb 
% 
NaCla 
%  
LiCla 
1  xt 7 22 
2 xt 5 21 
3 xc 46 27 
4 xc 42 30 
 
 
Due to the low number of signals in both the NOESY and ROESY spectra, there was 
ambiguity in assigning the trans-cis states of the two X-Pro bonds from the NOE patterns. 
Nonetheless, considerations on the influence of proximal and distal proline isomerization on 
the chemical shifts were used to gain insight into the proline isomerization in the peptide 
[36]. Specifically, since the F5HN was separated from the P3-P4 peptide bond by one 
covalent bond, greater chemical shift changes (d) were expected following isomerization 
of the proximal proline (i.e. P4), while minor changes were expected upon distal proline 
isomerization (i.e. P3). On this basis, the two F5HNs at 7.88 and 7.82 ppm (conformers 1 
and 2, respectively) and those at 7.33 and 7.21 ppm (conformers 3 and 4, respectively), 
which showed small differences of chemical shift (d1-2= 0.06 ppm and d3-4 = 0.12 
ppm), can result from the isomerization of the distal A2-P3 bond. 
On the other hand, the two sets of peaks (1-2 and 3-4), showing larger differences for the HN 
chemical shifts (dav1-2/3-4= 0.58 ppm), could a rise from the isomerization of the 
proximal P3-P4 peptide bond (Figure 10.4 A-B; Figure 10.6). 
 
 dHN 
1-2 0.06 
1-3 0.55 
1-4 0.67 
2-3 0.49 
2-4 0.61 
3-4 0.12 
 
Figure 10.5: Relative populations of cis and trans conformers in H-EPP-NH2. 
Figure 10.6: Chemical shift differences of the Phe5 HNs in the four cis/trans. 
conformers 
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Taking into account that the P3-P4 peptide bond in cis conformation seems to be more 
favored in NaCl than in LiCl, as indicated by the Chymotrypsin-coupled assay, conformers 
1 and 2 should have the P3-P4 peptide bond in trans conformation (conformers xt). 
Conversely, conformers 3 and 4 should correspond to the P3-P4 peptide bond in cis 
conformation (conformers xc).  
In this hypothesis, the cis P3-P4 population in NaCl is 88%, whereas in LiCl is 57%. 
Moreover, the A2-P3 bond seems to have the same cis and trans contents (about 50 % on 
the basis of the data reported in Figure 10.6) in both buffers. 
It is worth to note that in the case of conformers 3 and 4, the F5 HN chemical shift is up-
fielded and the two germinal Hβs appear as distinct signals, exhibiting their magnetic non 
equivalence and suggesting a more restricted rotation of the F5 ring. 
Moreover, the four cis-trans states gave also rise to multiple spin systems for the aliphatic 
protons of the Proline residues. Although the peaks assignment resulted intricate, we could 
observe a Proline Hα proton highly up-fielded (3.77 ppm), likely due to the close proximity 
of the P3-F5side-chains, as found in some proteins and peptide containing the segment P-P-
F [47], that gives rise to the ring current effect on Hα protons of the first Proline. 
Closely interacting P3-F5side-chains are supposed to be at the basis of the observed stability 
of the Proline-Proline cis conformers in the segment P-P-F, when present in a short peptide, 
devoid of any tertiary interaction. 
 
10.4 Development of a FRET-assay 
In order to develop a FRET-assay the selected EPP substrate was endowed with the 
FRET pair EDANS-Dabcyl [51]. 
EDANS-Dabcyl is a widely used donor-quencher pair. The optimal absorbance and 
emission wavelengths of EDANS are λabs  =  336 nm and λem  =  490 nm respectively, and for 
Dabcyl, the maximum absorbance wavelength is λabs  =  472 nm, which, to a large extent, 
overlap with the emission spectra of EDANS.  
When the two fluorophores are in close proximity (10–100 Å), the energy emitted from 
EDANS is quenched by Dabcyl. While the intact molecule is internally quenched, EDANS 
fluorescence is readily restored upon protease cleavage within the peptide chain and the 
intensity change can be detected continuously and directly [51, 52]. 
The substrate Ac-EK(Dabcyl)PPFAE(EDANS)KA-NH2 was efficiently synthesized, 
purified with a high yield (~40%) and characterized by mass spectrometry (Figure 10.7). 
  
 
 
 
 
 
In the intact FRET peptide, the fluorescence of EDANS is efficiently internally 
quenched by the Dabcyl in
(PBS1X) buffer at pH 7.4, as well.
fluorescence emission at 510 nm upon excitation at 340 nm, in a
between 5 to 100 ng/μL compared to 
same concentrations (Figure 10
Figure 10.8: Evaluation of concentration 
EK(Dabcyl)PPFAE(EDANS)KA
7.4 to have final concentrations of 100 ng/μL, 50 ng/μL, 25 ng/μL, 20 ng/μL, 15 ng/μL, 10 ng/μL
The intrinsic fluorescence and the quenching effects were evaluated recording spectra at wavelengths in the 
range of 450 – 500 nm. The peptide AE(EDANS)KA
as positive control. 
  
The incubation of recombinant 
in the specific enzymatic cleavage 
fluorescence intensity (λex/
CypA-mediated substrate isomerization.
Assay conditions were standardized manually and 
using a liquid handler and 384
Entry 
1 Ac-EK(Dabcyl)PPFAE(
2 H-
Figure 10.7: Sequences and analytical characterization of the FRET substrate.
 Hepes 5 mM, NaCl 150 mM and phosphate saline buffered 
 Indeed, the intact substrate showed a very low 
 
the chemically synthesized cleaved substrate used at 
.8). 
–dependent intrinsic fluorescence and quenching effect of Ac
-NH2 substrate. A stock solution of the substrate was diluted in PBS
-NH2 (2.5 ng/μL) were tested at the lowest concentration 
CypA at room temperature with the substrate result
by Chymotrypsin and a time-dependent increase of 
λem= 340nm/510 nm) that was linearly-related to the extent of 
 
subsequently validated in a HTS format 
-well black plates.  
SEQUENCE MWcalc M
EDANS)KA-NH2 1556.82 
AE(EDANS)KA-NH2 664.31 
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concentration range 
 
-
 1X at pH 
 and 5ng/μL. 
ed 
exp[M+H
+] 
1556.2 
665.6 
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In particular, firstly we investigated the influence of substrate and chymotrypsin 
concentration on the kinetic of EDANS release from the substrate in absence of the 
isomerase. Then, time-course experiments were optimize dusing four substrate 
concentrations (15, 25, 50 and 100 ng/μL) and four different substrate/chymotrypsin ratios 
(1:1, 1:5, 1:10 and 1:20 w/w) in a total volume of 50 μL in PBS 1X buffer at pH 7.4. 
The choice of the PBS1X as reaction buffer is due to the higher stability of the CypA over 
time in this compared to the buffer Hepes 5 mM, NaCl 150 mM, pH 7.4. 
As expected, a higher fluorescence emission was generated at increasing substrate 
concentrations and substrate-Chymotrypsin ratios (Figure 10.9). 
 
Figure 10.9: Evaluation of the optimal substrate/chymotrypsin ratios for the FRET-protease coupled cis-trans 
assay development. Time and dose – dependent – assays carried out using four different substrate 
concentrations:15 (A), 25 (B), 50 (C) and 100 (D) ng/μL, and four substrate/chymotrypsin ratios (1:1, 1:5, 1:10 
and 1:20 w/w) in a total volume of 50 μL. The fluorescence emitted at 510 nm was monitored upon excitation 
at 40 nm. Experiments were run as quadruplicate and reported as averaged values ± standard deviation (SD). 
 
However, the lowest fluorescence emissions were obtained using the substrate at 15 ng/μL 
and substrate/Chymotrypsin ratios of 1:1, 1:5 and 1:10, because in these conditions the 
hydrolysis reaction appare slower (Figure 10.9 A). 
We next optimized the concentration of CypA. As shown in Figure 10.10, the isomerization 
activity increased linearly with the increase of CypA concentrations from 25 to 600 ng/μL. 
 Optimal conditions for the assay, in terms of signal
amount of substrate were as follows: substrate concentration 
ng/μL (1:10 enzyme:substrate
Figure 10.10: Choice of CypA concentration for the FRET
Dose – dependent assays with three different substrate:
several concentration of CypA (from 25 to 600 ng/μL), in PBS 1X at pH 7.4 after 30 min of reaction time. The 
responses were calculated by su
Chymotrypsin cleavage.  
 
An optimal reaction time of 3
about 30 min and completed after 50
A-B). Under these conditions, an overall 
(Figure 10.11 A) was detected.
Figure 10.11: .Assay set up. (A
using the substrate at concentration of 15 ng/μL, the chymotrypsin at 150 ng/μL and the CypA at 600 ng/μL in 
PBS1X at pH 7.4.(B) Time-dependent
and CypA at 600 ng/μL, in PBS 1X at pH 7.4. Experime
values ± standard deviation (SD).
-to-noise (S/N) values, react
15 ng/μL, chymo
 ratio), CypA 600 ng/μL. 
-protease coupled cis-trans
 chymotrypsin ratios (1:1, 1:5 and 1:10 w/w) and using 
btracting the signal obtained during the CypA-assisted and not assisted 
0 min was chosen, because substrate processing was linear for 
 min under our experimental condi
signal of around 800 normalized
 
) Time course of FRET-chymotrypsin coupled cis-trans
 assay (in 30 min) using EPP at 15 ng/μL, Chymotrypsin at 150 ng/μL 
nts were run as quadruplicate and reported as averaged 
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ion time and 
trypsin 150 
 
 assay development. (A) 
tions (Figure 10.11 
 fluorescence units 
 
 isomerization assay 
 The enzyme reaction follow
reaction (v) increasing with substrate concentration 
Figure 10.12: Kinetic constants determination of FRET
Michelis and Menten and Lineweaver
isomerization of EPP substrate. Increasing concentration of EPP
Chymotrypsin at 150 ng/μL in PBS 1X at pH 7.4 and incubated for 30 min.
 
A first order rate kinetic was observed and a double reciprocal Lineweaver
against 1/[S] gave values of 
condition (PBS 1X , pH 7
agreement with the value reported in literature (1.4 x 10
chymotrypsin – coupled PPIase assay, u
substrate N-succinyl-AAPF
(vol/vol) aqueous dimethyl sulfoxide 
 
10.5 Assay Procedure Automation and Validation
The assay procedure descri
using an integrated platform comprising 
robotic arm and a multi-well
The assay was performed also in
3%) to simulate the experimental
this solvent are submitted to screening
of signal-to-noise (S/N) and 
 As can be seen in 
determined for the assays 
ed the Michaelis-Menten kinetics with the velocity of the 
(S) (Figure 10.12). 
-Chymotrypsin cis-trans 
-Burk plots, respectively, for the CypA catalyzed 
 were mixed to CypA at 600 ng/μL and 
 
kcat/Km of 2.5x107 M-1 s-1 at room temperature in physiological 
.4) (Figure 10.12 B). The kinetic constant here determined is in 
7 M-1 s-1), calculated with the 
sing the recombinant wild type CypA and the 
-pNA dissolved in Hepes 35 mM buffer (pH 8.0)
at 10 C [53]. 
 
bed for the manual experiments, 
a 8-channel Starlet station for liquid handling, a 
 plate reader (EnSpire Multimode Plate Readers
 the presence of increasing amounts of DMSO (1%, 2% and 
 conditions whereby compounds from stock solutions in 
. Optimal assay performances were evaluated in terms 
Z'-factor values. 
Figure 10.13 excellent S/N values of 11.6, 
without DMSO and in the presence of 1 
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coupled assay. (A, B) 
cis-trans prolyl 
-Burke plot of 1/v 
 and 66% 
was next automated 
, Perkin Elmer). 
11.1 and 10.9 were 
and 2 % solvent, 
 respectively; the S/N value decreased to 9.1 at 3% DMSO.
The Z'-factor values determined in the absence DMSO and at 1 and 2% solvent were 
0.75 and 0.68, respectively, while in the presence of 3% DMSO the value decreased to 0.56. 
Altogether, data suggest that Z’
assay in screening campaigns at the highest solvent concentration tested
Figure 10.13: Evaluation of FRET 
determine the suitability of the assay for high
(B) with and without DMSO. (C
percentage of residual activity, determined by the FRET
compounds. (D) Dose-dependent assays with three selected hits, CsA, C3353, D138 and a negative control 
(C3909). Data were fitted and the IC50 determined by non
In order to estimate the assay 
library (n = 1,280 compounds
format using laboratory automation equipment (
 
-factor and S/N values are still sufficiently high for usi
- assay performance. Thirty-twowells of a 384-
-throughput screening in terms of S/N (
) Screening of 298 compounds of LOPAC library tested. The plot reported the 
-assay, of CypA after an hour incubation with 
-linear regression analysis.  
suitability for HTS, a pilot screen against t
) was performed. Assays were transferred 
Microlab star line, Hamilto
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0.80, 
ng the 
. 
 
well plates were used to 
A) and Z'-factor values 
he LOPAC 
in 384 well plate 
n™) and a final 
 concentration of LOPAC compounds 
supplemented with DMSO 1% 
In Figure 10.13 C results obtained on the 298 compounds are reported.
of compounds, three were selecte
They were: N2-(cis-2
diamine hydrochlorid (LOPAC code
D138); and as expected also the CsA, present within the set. D
C3909), instead, was used in the next assays as negative control. 
The testing was performed in a fourteen
at a 1:2 serial dilution. As shown in Figure 10
underlined by an IC50 of 100
The compound D138, inhibited the isomerase activity in dose dependent manner without 
reaching the saturation in the concentration range tested, suggesting a weaker affinity for 
CypA compared to CsA. On the other hand
expected, did not provide inhibition of isomerase activity. 
Compound C3353 provided a strong dos
complete at 25 μM. The estimated IC
compound C3353 with CypA was assessed
Material and Methods section for details).
versus ligand concentration was fitted with a one
providing a KD of 6 μM, in agreement with the IC
 
 
Figure 10.14: CypA Fluorescence titration with
intensities normalized (dots) are fitted
of 50 μM in quadruplicate in PBS 1X at pH 7.4, 
(Figure 10.13 B). 
d for further characterization.  
-Aminocyclohexyl)-N6-(3-chlorophenyl)-9-
 C3353), 5,7-Dichlorokynurenicacid
-cycloserine (LOPAC code 
 
-point dose-response format in quadruplicate
.13 D, CsA provided a strong inhibi
 nM, in agreement with other reports [53]. 
, compound C3909, used as negative control,
 
e-dependent inhibition which was nearly 
50 for this compound was 4 μM. Direct binding of 
 using fluorescence quenching assays (see 
 A plot of the corrected fluorescence intensity 
-site binding model (Figure 
50 determined in the HTS assay.
 the C3353 molecule. The measured fluorescence 
 with a nonlinear regression curve (line).
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 From this set 
ethyl-9H-purine-2,6-
 (LOPAC code 
 
tion 
 as 
10.14), 
 
 
 
 10.6 Molecular Docking studies of C3353 and D138 
Molecular docking simulations were carried out to investigate the binding modes of 
the novel inhibitors identified in the HTS and with the aim to interpret the experimental 
binding data. First, to identify which docking protocol and which protein conforma
more suitable for our compounds, we performed a self
human CypA complexes available in the protein data bank (PDB).
We selected four complexes in which 
code: 3RDD, 4N1N, 4N1Q a
software, we compared the ability of 17 different protocols in reproducing the four complex 
conformations (see Methods
geometries were nicely reprodu
 
Figure 10.15: Results of the docking benchmark study on human CypA. (
(RMSDmin) performed by the tested docking protocol (y
values); (B) Average RMSD values (RMSDave); (
protocol with a RMSD value lower than the X
is a resuming score based on the RMSDmin, RMSDave, N
represented by a colour scheme, blue spots identify the best obtained results.
 
-docking benchmark based on the 
 
a unique binding mode was present (PDB 
nd 4N1R). In the benchmark performed with Dockbench 
 section for details). Except for 4N1N, all the complex 
ced by several protocols (Figure 10.15) 
A) Minimum RMSD values 
-values) for the considered complex structures (x
C) Total numbers of conformations returned by the docking 
-ray crystal resolution (N(RSMD < R)); (
-RMSD on a 0–3 points sca
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tion were 
 
-
D) The Protocol Score 
le. Values are 
 In order to dock D138 and C3353, we selected the protein conformation extracted 
from the complex with PDB code 3RDD due to the highe
to C3353. Among the 17 protocols, for the 3RDD complex the GOLD program coupled with 
Goldscore scoring function was the protocol show
benchmark study. Molecular docking studies of both compounds revealed 
mode, in which a unique cluster of conformation
the strongest inhibitor, C3353, the molecule adopts a conformation that is nicely 
accommodated in the active site of CypA (
Figure 10.16: Molecular docking studies of D138 and C3353 compounds. In panels A and 
mode of C3353 is reported. In A
of CypA is shown; in B, the 3D-
The surface of CypA is colored according the hydrophobic propensity of the residues forming the active site 
(the hydrophobic and hydrophilic 
In Panels B and D, the binding mode of D138 is shown. Similarly to C3353, both the 2D depiction of the main 
interactions (panel B) and the highest score conformation (panel D) are reported using the same color schem
In Panel E, the per-residue analysis of the protein
In the histogram two component of the interaction energy are computed independently for the residues mostly 
involved in the binding. 
st similarity in th
ing the best per
s was present for each ligand. In the case of 
Figure 10.16, panels A and C). 
, a schematic depiction of the more relevant interactions with the catalytic site 
conformation with highest score resulted in the docking simulation is reported. 
features are respectively coded into a green to violet palette color scheme). 
-ligand interaction for C3353 (red) and D138 ligands(green). 
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e size of its ligand 
formance in the 
a clear binding 
 
 
C, the binding 
e. 
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The chorophenyl moiety lies in a hydrophobic pocket formed by F60, F113 and L122, 
while the aminocyclohexyl group occupies a more hydrophilic groove defined by G72, S110, 
Q111, S119, and T107. In particular, the aminocyclohexyl conformation is stabilized by the 
presence of a hydrogen bond with the backbone of G72.  
The purinic core occupies a third site connecting the two previously mentioned pocket and 
mainly interacts with R55; the ethyl moiety at N9 increment the shape complementarity with 
the protein surface. 
The 5,7-dichlorokynurenic acid (D138) showed a clear propensity for the hydrophilic 
groove of the CypA catalytic site. The carboxylic moiety establishes two hydrogen bonds 
with S110 and Q111 while the condensed ring lies in front to the methyl group of A103 (Figure 
10.16, panels B and D).  
The molecular basis explaining the different ability to inhibit the CypA enzymatic activity 
can be ascribed to the different size of the two compounds and to the number of interactions 
they are able to establish with the catalytic site.  
In particular, C3353 is able to occupy most of the catalytic cleft and the final score 
returned by Goldscore function was clearly higher than for D138, respectively 76.8 and 48.6.  
These observations are more evident when the contribution to the estimated interaction 
energy of the two compounds are plotted in a per-residue histogram as reported in the panel 
E of the Figure 10.16. 
In this graph, the electrostatic interaction energy and a hydrophobic score are computed for 
each residue of the binding site and the most relevant ones are reported. While the 
electrostatic component of the predicted interaction energy is relevant for both ligands, the 
hydrophobic score is notably weaker in D138 that interact only with A103.  
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11.  DISCUSSION 
The peptidyl-prolyl cis-trans isomerases represent a large class of biological 
proteins, such as the cyclophilins, with broad physiological functions, making them valid 
targets for therapeutic intervention [54].  
For example, cyclophlin inhibitors have shown promise as replication inhibitors of several 
RNA viruses including HIV, HCV, SARS corona virus and influenza virus [54]. 
Non-immunosuppressive cyclosporin derivatives [54, 55, 56] have reached clinical 
development for the treatment of hepatitis C infection. Moreover, formulations of 
cyclosporin itself have also shown some promise in new therapeutic applications, for 
example in traumatic brain injury [57], muscular dystrophy [58], respiratory disease [59], 
cardiovascular disease [60] and Alzheimer’s disease [61].  
In this framework, many efforts are spent on selecting specific PPIase modulators for 
therapeutic approaches. However, the discovery of novel inhibitors has been limited by the 
lack of suitable assays for HTS. 
The biochemical reaction catalyzed by PPIases interconverts cis and trans isomers of 
a proline peptide bond. However, this reaction also occurs spontaneously in the absence of 
catalysis within a few minutes, especially in short synthetic peptide substrates.  
Inhibitor screens therefore have to distinguish between the catalyzed and the spontaneous 
reactions, which are separated by a time window of a few minutes [62].  
Such screens have been developed, but they require low temperatures and elaborated 
experimental protocols in the presence of organic solvent [19]; they therefore are invariably 
of low throughput and are unsuitable for large scale screens [53]. 
Here, we developed and optimized a simple and robust homogenous fluorescent HTS 
assays for the discovery of Cyclophilin inhibitors in 384-well plates, using a new FRET-
based substrate probe useful for Chymotrypsin-coupled isomerase assays. The probe, easily 
prepared by a straightforward solid phase approach in a highly soluble form, contains the 
well-known FRET pair Dabcyl-EDANS [50,51]. 
The donor (EDANS) is separated from the quencher (Dabcyl) by a short peptide linker 
containing a modified Chymotrypsin cleavage site (Pro-Phe), and residues of Glutamic acids 
and Lysine at the N- and C- termini, respectively, to potentially increase the cis 
conformation is solution.  
Noteworthy, the NMR structural characterization of the probe showed that the cis 
conformation of the substrate was highly favored, as hypothesized in the design.  
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Treatment of the substrate with recombinant CypA in absence of organic solvents, promoted 
the rapid proteolytic cleavage by Chymotrypsin and an increase of fluorescence intensity 
that is linearly related to the extent of CypA-mediated substrate isomerization. 
Technical parameters of the HTS assay (Z′-factor, S/N, IC50 values of 
pharmacological control) have been optimized therefore the test appears to be ready for 
large scale screenings. As an exemplary screening we used here the commercial LOPAC1280 
library. From such screening some selective CypA inhibitors were identified, including the 
well-known CsA, present within the library as a positive control. 
Among the other compounds showing activity, two were tested in dose response 
experiments. 
The purine-based compound C3353, known as a Cdk inhibitor selective for Cyclin-
dependent kinase-1 (Cdk1) (PMID: 21131960), showed a 6 μM IC50 inhibition, which is a 
good starting point for developing new and more selective inhibitors. 
To gain insights into the structure-activity relationship of the two compounds, they were 
subjected to a comparative computational study that confirmed the predilection of the 
ligands for the CypA active site. 
Moreover, the different IC50 values detected can be explained by the higher number of 
interactions established by C3353 with the hydrophobic groove present in the catalytic site. 
In conclusion, we have set up a HTS screening assay for the selection of CypA cis-
trans isomerase activity inhibitors. The assay is based on the use of a new fluorescent 
peptide substrate we have designed in order to have a high proportion of cis conformers and 
to work by following fluorescence intensity increase or decrease, depending on enzyme 
activation or inhibition.  
The assay is very robust, has been optimized on 384 well plates and can be used in screening 
campaigns of large compound libraries.  
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